Methods and compositions for CNS delivery of iduronate-2-sulfatase

A stable intrathecal formulation of I2S with polysorbate and sodium chloride enables effective delivery across brain regions, addressing the limitations of current therapies by enhancing enzyme replacement in lysosomal storage disorders.

JP7591476B2Active Publication Date: 2024-11-28TAKEDA PHARMA CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021133184
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2011-06-09
Filing Date
2021-08-18
Publication Date
2024-11-28
Estimated Expiration
2031-06-25

AI Technical Summary

Technical Problem

Current enzyme replacement therapies struggle to effectively deliver therapeutic agents across the blood-brain barrier (BBB) for the treatment of lysosomal storage disorders due to limited diffusion and invasive delivery methods, which often result in insufficient therapeutic effects and complications.

Method used

A stable formulation for intrathecal administration of iduronate-2-sulfatase (I2S) protein, combined with polysorbate surfactant and sodium chloride, allows for high-concentration delivery into the cerebrospinal fluid, enabling broad diffusion across brain regions without significant immune response.

Benefits of technology

The formulation achieves efficient and minimally invasive delivery of I2S to various brain regions, reducing lysosomal storage disease symptoms and enzyme activity, with reduced side effects and improved therapeutic outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591476000030
    Figure 0007591476000030
  • Figure 0007591476000031
    Figure 0007591476000031
  • Figure 0007591476000032
    Figure 0007591476000032
Patent Text Reader

Abstract

To provide methods and compositions for CNS delivery of iduronate-2-sulfatase.SOLUTION: The invention provides, in particular, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage disorders. The invention includes a stable formulation for direct CNS intrathecal administration, where the formulation comprises iduronate-2-sulfatase (I2S) protein, a salt and a polysorbate surfactant. In some embodiments, the invention includes a method for treating Hunters Syndrome comprising a step of intrathecally administering the formulation of any one of embodiments to a subject in need of treatment.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Patent Applications Nos. 61 / 358,857, filed June 25, 2010; 61 / 360,786, filed July 1, 2010; 61 / 387,862, filed September 29, 2010; 61 / 435,710, filed January 24, 2011; 61 / 442,115, filed February 11, 2011; 61 / 476,210, filed April 15, 2011; and 61 / 495,268, filed June 9, 2011, the contents of each of which are incorporated herein by reference. This application is related to U.S. patent applications entitled "Methods and Compositions for CNS Delivery of Heparan N-Sulfatase" (filed on the same day); "Methods and Compositions for CNS Delivery of Iduronate Sulfatase" (filed on the same day); "Methods and Compositions for CNS Delivery of β-galactocerebrosidase" (filed on the same day); "Methods and Compositions for CNS Delivery of Arylsulfatase A" (filed on the same day); and "Treatment of Sanfilippo Syndrome Type B" (filed on the same day), each of which is incorporated herein by reference.

[0002] This application is related to U.S. patent applications entitled "Methods and Compositions for CNS Delivery of Heparan N-Sulfatase" (filed on the same day); "Methods and Compositions for CNS Delivery of Iduronate Sulfatase" (filed on the same day); "Methods and Compositions for CNS Delivery of β-galactocerebrosidase" (filed on the same day); "Methods and Compositions for CNS Delivery of Arylsulfatase A" (filed on the same day); and "Treatment of Sanfilippo Syndrome Type B" (filed on the same day), each of which is incorporated herein by reference. [Background technology]

[0003] Enzyme replacement therapy (ERT) involves the systemic administration of natural or recombinantly derived proteins and / or enzymes to a subject. Approved therapies are typically administered intravenously to a subject and are generally effective in treating the physical symptoms of underlying enzyme deficiency. As a result of the limited distribution of intravenously administered proteins and / or enzymes in the cells and tissues of the central nervous system (CNS), the treatment of diseases with CNS etiology has been particularly challenging, as intravenously administered proteins and / or enzymes do not adequately cross the blood-brain barrier (BBB).

[0004] The blood-brain barrier (BBB) ​​is a structural system composed of endothelial cells that functions to protect the central nervous system (CNS) from harmful substances in the bloodstream, such as bacteria, macromolecular substances (e.g., proteins), and other hydrophilic molecules, by restricting diffusion of such substances across the BBB into the underlying cerebrospinal fluid (CSF) and the CNS.

[0005] There are several ways to bypass the BBB to enhance brain delivery of therapeutics, including direct intracerebral injection, transient permeabilization of the BBB, and modification of active agents to change tissue distribution. Direct injection of therapeutics into brain tissue completely bypasses the vasculature, but mainly suffers from the risks of complications (infection, tissue damage, immune responsiveness) incurred by intracranial injection, as well as poor diffusion of active agents from the administration site. To date, direct administration of proteins into brain matter has not achieved significant therapeutic effects due to diffusion barriers and limited doses of therapeutics that can be administered. Convective diffusion by catheters placed in the brain parenchyma with slow long-term infusion (Non-Patent Document 1; Non-Patent Document 2) has been studied, but there is no approved therapy that generally uses this approach for long-term therapy. Furthermore, placement of intracerebral catheters is highly invasive, making it less desirable as a clinical alternative.

[0006] Intrathecal (IT) injection or administration of proteins into the cerebrospinal fluid (CSF) have also been attempted, but have not yet seen therapeutic success. A major challenge in this procedure is the tendency of the active agents to bind very tightly to the ependymal lining of the ventricles, which prevents subsequent diffusion. In general, there are no approved substances for the treatment of brain genetic diseases by direct administration into the CSF. Indeed, the barriers to diffusion at the brain's surface, as well as the lack of effective and convenient delivery methods, have been considered by many to be too great an obstacle to achieve adequate therapeutic effects in the brain for any disease. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Bobo, et al., Proc. Natl. Acad. Sci. USA 91, 2076-2080 (1994) [Non-Patent Document 2] Nguyen, et al. J. Neurosurg. 98, 584-590 (2003)) Summary of the Invention [Problem to be solved by the invention]

[0008] Many lysosomal storage disorders affect the nervous system, and therefore present unique challenges in treating these diseases with traditional therapies. Large accumulations of glycosaminoglycans (GACs) are often found in the neurons and meninges of affected individuals, resulting in various types of CNS symptoms. To date, CNS symptoms resulting from lysosomal disorders have been successfully treated by any available means.

[0009] Thus, there remains a great need for effective delivery of therapeutic agents to the brain. More specifically, there is a great need for more effective delivery of active agents to the central nervous system for the treatment of lysosomal storage disorders. [Means for solving the problem]

[0010] The present invention provides an effective and minimally invasive approach for the direct delivery of therapeutic agents to the central nervous system (CNS). The present invention is based, in part, on the unexpected discovery that replacement enzymes for lysosomal storage diseases (e.g., iduronate-2-sulfatase (I2S)) can be introduced directly into the cerebrospinal fluid (CSF) of subjects in need of treatment at high concentrations (e.g., about 3 mg / mg or more, 4 mg / ml, 5 mg / ml, 10 mg / ml or more) such that the enzymes effectively and widely diffuse across various surfaces and penetrate various regions across the brain, including deep brain regions. Even more unexpectedly, the inventors have demonstrated that such high protein concentration delivery can be achieved using simple saline or buffer-based formulations and without inducing substantial side effects in the subject, such as severe immune responses. Thus, the present invention provides a highly efficient, clinically desirable, and patient-friendly approach for direct CNS delivery for the treatment of various diseases and disorders having a CNS component, particularly lysosomal storage diseases. The present invention represents a significant advance in the fields of CNS targeting and enzyme replacement therapy.

[0011] As described in detail below, the present inventors have successfully developed a stable formulation for effective intrathecal (IT) administration of iduronate-2-sulfatase (I2S) protein. However, it is believed that the various stable formulations described herein are generally suitable for CNS delivery of therapeutic agents, including various other lysosomal enzymes. In fact, the stable formulations according to the present invention can be used for CNS delivery via various techniques and routes, including but not limited to intraparenchymal administration, intracerebral administration, intracerebroventricular (ICV) administration, intrathecal administration (e.g., IT-lumbar, IT-cisterna) administration, and any other technique and route for direct or indirect injection into the CNS and / or CSF.

[0012] The various stable formulations described herein are generally suitable for CNS delivery of other therapeutics, such as therapeutic proteins, including various replacement enzymes for lysosomal storage diseases. In some embodiments, the replacement enzymes can be synthetic, recombinant, gene-activated, or native enzymes.

[0013] In various embodiments, the invention encompasses a stable formulation for direct CNS intrathecal administration comprising iduronate-2-sulfatase (I2S) protein, a salt, and a polysorbate surfactant. In some embodiments, the I2S protein is present at a concentration ranging from approximately 1-300 mg / ml (e.g., 1-250 mg / ml, 1-200 mg / ml, 1-150 mg / ml, 1-100 mg / ml, 1-50 mg / ml). In some embodiments, the I2S protein is present at or up to a concentration selected from 2 mg / ml, 3 mg / ml, 4 mg / ml, 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml, 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, 100 mg / ml, 150 mg / ml, 200 mg / ml, 250 mg / ml, or 300 mg / ml.

[0014] In various embodiments, the invention encompasses a stable formulation of any of the embodiments described herein, wherein the I2S protein comprises the amino acid sequence of SEQ ID NO:1. In some embodiments, the I2S protein comprises an amino acid sequence at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% identical to SEQ ID NO:1. In some embodiments, the stable formulation of any of the embodiments described herein comprises a salt. In some embodiments, the salt is NaCl. In some embodiments, the NaCl is present at a concentration in the range of approximately 0-300 mM (e.g., 0-250 mM, 0-200 mM, 0-150 mM, 0-100 mM, 0-75 mM, 0-50 mM, or 0-30 mM). In some embodiments, the NaCl is present at a concentration in the range of approximately 137-154 mM. In some embodiments, the NaCl is present at a concentration of approximately 154 mM.

[0015] In various embodiments, the invention encompasses a stable formulation of any of the embodiments described herein, wherein the polysorbate surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and combinations thereof. In some embodiments, the polysorbate surfactant is polysorbate 20. In some embodiments, the polysorbate 20 is present at a concentration ranging from approximately 0 to 0.02%. In some embodiments, the polysorbate 20 is present at a concentration of approximately 0.005%.

[0016] In various embodiments, the invention encompasses a stable formulation of any of the embodiments described herein, wherein the formulation further comprises a buffer. In some embodiments, the buffer is selected from the group consisting of phosphate, acetate, histidine, succinate, Tris, and combinations thereof. In some embodiments, the buffer is phosphate. In some embodiments, the phosphate is present at a concentration of 50 mM or less (e.g., 45 mM, 40 mM, 35 mM, 25 mM, 20 mM, 15 mM, 10 mM, or 5 mM or less). In some embodiments, the phosphate is present at a concentration of 20 mM or less. In various aspects, the invention encompasses a stable formulation of any of the embodiments described herein, wherein the formulation has a pH of about 3-8 (e.g., about 4-7.5, 5-8, 5-7.5, 5-6.5, 5-7.0, 5.5-8.0, 5.5-7.7, 5.5-6.5, 6-7.5, or 6-7.0). In some embodiments, the formulation has a pH of about 5.5-6.5 (e.g., 5.5, 6.0, 6.1, 6.2, 6.3, 6.4, or 6.5). In some embodiments, the formulation has a pH of about 6.0.

[0017] In various embodiments, the invention encompasses a stable formulation of any of the embodiments described herein, which is a liquid formulation. In various embodiments, the invention encompasses a stable formulation of any of the embodiments described herein, which is formulated as a lyophilized powder.

[0018] In some embodiments, the stable formulation for intrathecal administration includes iduronate-2-sulfatase (I2S) protein at a concentration ranging from about 1 to 300 mg / ml, NaCl at a concentration of about 154 mM, polysorbate 20 at a concentration of about 0.005%, and a pH of about 6.0. In some embodiments, the I2S protein is present at a concentration of about 10 mg / ml. In some embodiments, the I2S protein is present at a concentration of about 30 mg / ml, 40 mg / ml, 50 mg / ml, 75 mg / ml, 100 mg / ml, 150 mg / ml, 200 mg / ml, 250 mg / ml, or 300 mg / ml.

[0019] In various embodiments, the present invention encompasses a container that contains a single dose of the stable formulation in various embodiments described herein. In some embodiments, the container is selected from an ampoule, a vial, a bottle, a cartridge, a reservoir, a lyo-ject, or a pre-filled syringe. In some embodiments, the container is a pre-filled syringe. In some embodiments, the pre-filled syringe is selected from a borosilicate glass syringe with a baked silicone coating, a borosilicate glass syringe with sprayed silicone, or a plastic resin syringe that does not contain silicone. In some embodiments, the stable formulation is present in a volume of less than about 50 mL (e.g., 45 mL, 40 mL, 35 mL, 30 mL, 25 mL, 20 mL, 15 mL, 10 mL, 5 mL, 4 mL, 3 mL, 2.5 mL, 2.0 mL, 1.5 mL, 1.0 mL, or 0.5 mL or less). In some embodiments, the stable formulation is present in a volume of about 3.0 mL or less.

[0020] In various aspects, the invention encompasses a method of treating Hunter Syndrome, comprising the step of intrathecally administering to a subject in need of treatment a formulation according to any of the embodiments described herein.

[0021] In some embodiments, the invention encompasses a method of treating Hunter syndrome comprising administering intrathecally to a subject in need of treatment a formulation comprising iduronate-2-sulfatase (I2S) at a concentration ranging from approximately 1-300 mg / ml, NaCl at a concentration of about 154 mM, polysorbate 20 at a concentration of about 0.005%, and a pH of about 6.

[0022] In some embodiments, the intrathecal administration does not result in substantial side effects (e.g., severe immune responses) in the subject. In some embodiments, the intrathecal administration does not result in a substantial adaptive T cell-mediated immune response in the subject.

[0023] In some embodiments, intrathecal administration of the formulation results in delivery of the I2S protein to various target tissues in the brain, spinal cord, and / or peripheral organs. In some embodiments, intrathecal administration of the formulation results in delivery of the I2S protein to target brain tissues. In some embodiments, the brain target tissues include neurons in white matter and / or gray matter. In some embodiments, the I2S protein is delivered to neurons, glial cells, perivascular cells, and / or meningeal cells. In some embodiments, the I2S protein is further delivered to neurons in the spinal cord.

[0024] In some embodiments, intrathecal administration of the formulation further results in systemic delivery of the I2S protein to a peripheral target tissue, in some embodiments, the peripheral target tissue is selected from the liver, kidney, pancreas, and / or heart.

[0025] In some embodiments, intrathecal administration of the formulation causes cellular lysosomal localization in brain target tissue, spinal cord neurons and / or peripheral target tissue. In some embodiments, intrathecal administration of the formulation reduces GAG accumulation in brain target tissue, spinal cord neurons and / or peripheral target tissue. In some embodiments, GAG accumulation is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1-fold, 1.5-fold, or 2-fold compared to a control (e.g., GAG accumulation in a subject before treatment). In some embodiments, intrathecal administration of the formulation reduces neuronal vacuolation (e.g., by at least 20%, 40%, 50%, 60%, 80%, 90%, 1-fold, 1.5-fold, or 2-fold compared to a control). In some embodiments, the neuron comprises a Purkinje cell.

[0026] In some embodiments, intrathecal administration of the formulation results in an increase in I2S enzyme activity in brain target tissues, spinal cord neurons and / or peripheral target tissues, in some embodiments, the I2S enzyme activity is increased by at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or 10-fold compared to a control (e.g., endogenous enzyme activity in the subject prior to treatment). In some embodiments, the increase in I2S enzyme activity is at least about 10 nmol / hr·mg, 20 nmol / hr·mg, 40 nmol / hr·mg, 50 nmol / hr·mg, 60 nmol / hr·mg, 70 nmol / hr·mg, 80 nmol / hr·mg, 90 nmol / hr·mg, 100 nmol / hr·mg, 150 nmol / hr·mg, 200 nmol / hr·mg, 250 nmol / hr·mg, 300 nmol / hr·mg, 350 nmol / hr·mg, 400 nmol / hr·mg, 450 nmol / hr·mg, 500 nmol / hr·mg, 550 nmol / hr·mg, or 600 nmol / hr·mg.

[0027] In some embodiments, I2S enzyme activity is increased in the lumbar region, hi some embodiments, increased I2S enzyme activity in the lumbar region is at least about 2000 nmol / hr·mg, 3000 nmol / hr·mg, 4000 nmol / hr·mg, 5000 nmol / hr·mg, 6000 nmol / hr·mg, 7000 nmol / hr·mg, 8000 nmol / hr·mg, 9000 nmol / hr·mg, or 10,000 nmol / hr·mg.

[0028] In some embodiments, intrathecal administration of the formulation reduces the intensity, severity, or frequency of, or causes delayed onset of, at least one symptom or characteristic of Hunter syndrome. In some embodiments, at least one symptom or characteristic of Hunter syndrome is cognitive impairment; white matter lesions; dilated perivascular spaces in the brain parenchyma, ganglia, corpus callosum, and / or brain stem; atrophy, and / or ventricular enlargement.

[0029] In some embodiments, the intrathecal administration is performed once every two weeks. In some embodiments, the intrathecal administration is performed once a month. In some embodiments, the intraosseous administration is performed once every two months. In some embodiments, the administration interval is twice a month. In some embodiments, the administration interval is once every week. In some embodiments, the administration interval is twice or several times a week. In some embodiments, the administration is continuous, such as through a continuous infusion pump. In some embodiments, the intrathecal administration is used in conjunction with intravenous administration. In some embodiments, the intravenous administration is no more frequent than once a week. In some embodiments, the intravenous administration is no more frequent than once every two weeks. In some embodiments, the intravenous administration is no more frequent than once a month. In some embodiments, the intravenous administration is no more frequent than once every two months. In certain embodiments, the intravenous administration is more frequent than monthly administration, such as twice a week, weekly, biweekly, or twice a month.

[0030] In some embodiments, intravenous and intrathecal administration are performed on the same day. In some embodiments, intravenous and intrathecal administration are not performed within a certain time of each other, for example, within at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, or at least 1 week. In some embodiments, intravenous and intrathecal administration are performed on an alternating schedule, for example, once a week, every other week, twice a month, or once a month. In some embodiments, intrathecal administration can be substituted for intravenous administration every third or fourth or fifth administration of the schedule, for example, once a week, every other week, twice a month, or once a month.

[0031] In some embodiments, intravenous administration can be substituted for intrathecal administration every third or fourth or fifth dose of the schedule, for example, weekly, biweekly, twice-monthly or monthly. In some embodiments, intravenous and intrathecal administration are performed sequentially, for example, intravenous administration is performed first (e.g., weekly, biweekly, twice-monthly or monthly dose administration for 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months or 1 year or more), followed by intrathecal administration (e.g., weekly, biweekly, twice-monthly or monthly dose administration for more than 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months or 1 year or more). In some embodiments, intrathecal administration is performed first (e.g., weekly, biweekly, twice-monthly, monthly, bimonthly, or trimonthly dosages for 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or 1 year or more), followed by intravenous administration (e.g., weekly, biweekly, twice-monthly, or monthly dosages for more than 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or 1 year or more).

[0032] In some embodiments, intrathecal administration is used in the absence of intravenous administration.

[0033] In some embodiments, intrathecal administration is used in the absence of concomitant immunosuppressive therapy.

[0034] The drawings are for illustrative purposes only and are not limiting. In one embodiment, for example, the following items are provided: (Item 1) A stable formulation for intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, a salt, and a polysorbate surfactant. (Item 2) 2. The stable formulation according to item 1, wherein the I2S protein is present at a concentration ranging from about 1 to 300 mg / ml. (Item 3) 3. The stable formulation of item 1 or 2, wherein the I2S protein is present at a concentration selected from 2 mg / ml, 10 mg / ml, 30 mg / ml, 50 mg / ml, or 100 mg / ml. (Item 4) 4. The stable formulation according to any one of items 1 to 3, wherein the I2S protein comprises the amino acid sequence of SEQ ID NO:1. (Item 5) 5. The stable formulation according to any one of items 1 to 4, wherein the salt is NaCl. (Item 6) 6. The stable formulation according to item 5, wherein the NaCl is present at a concentration in the range of about 0 to 300 mM. (Item 7) 5. The stable formulation according to item 4, wherein the NaCl is present at a concentration in the range of about 137 to 154 mM. (Item 8) 8. The stable formulation of item 7, wherein the NaCl is present at a concentration of about 154 mM. (Item 9) 9. The stable formulation according to any one of items 1 to 8, wherein the polysorbate surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and combinations thereof. (Item 10) 10. The stable formulation of item 9, wherein the polysorbate surfactant is polysorbate 20. (Item 11) 11. The stable formulation according to item 10, wherein the polysorbate 20 is present at a concentration ranging from about 0 to 0.02%. (Item 12) 12. The stable formulation of item 11, wherein the polysorbate 20 is present in a concentration ranging from about 0.005%. (Item 13) 13. The stable formulation according to any one of items 1 to 12, wherein the formulation further comprises a buffering agent. (Item 14) Item 14. The stable formulation of item 13, wherein the buffer is selected from the group consisting of phosphate, acetate, histidine, succinate, tristris, and combinations thereof. (Item 15) 15. The stable formulation according to item 14, wherein the buffer is a phosphate. (Item 16) 16. The stable formulation according to item 15, wherein the phosphate is present in a concentration not exceeding 50 mM. (Item 17) 14. The stable formulation according to item 13, wherein the phosphate is present in a concentration not exceeding 20 mM. (Item 18) 18. The stable formulation according to any one of items 1 to 17, wherein the formulation has a pH of about 3 to 8. (Item 19) 19. The stable formulation according to item 18, wherein the formulation has a pH of about 5.5 to 6.5. (Item 20) 20. The stable formulation of item 19, wherein the formulation has a pH of about 6.0. (Item 21) 21. The stable formulation according to any one of items 1 to 20, wherein the formulation is a liquid formulation. (Item 22) 21. The stable formulation according to any one of items 1 to 20, wherein the formulation is formulated as a lyophilized dry powder. (Item 23) 1. A stable formulation for intrathecal administration comprising iduronate-2-sulfatase (I2S) protein at a concentration ranging from about 1 to 300 mg / ml, NaCl at a concentration of about 154 mM, polysorbate 20 at a concentration of about 0.005%, and a pH of about 6.0. (Item 24) 24. The stable formulation of item 23, wherein the I2S protein is present at a concentration of about 10 mg / ml. (Item 25) 24. The stable formulation of item 23, wherein the I2S protein is present at a concentration of about 30 mg / ml, 50 mg / ml, 100 mg / ml, or 300 mg / ml. (Item 26) 26. A container comprising a single-dose form of the stable formulation according to any one of items 1 to 25. (Item 27) 27. The container according to item 26, wherein the container is selected from an ampoule, a vial, a cartridge, a reservoir, a lyo-ject, or a pre-filled syringe. (Item 28) The container according to any one of items 26 to 28, wherein the container is a pre-filled syringe. 29. The container according to item 28, wherein the pre-filled syringe is selected from a borosilicate glass syringe with a baked silicone coating, a borosilicate glass syringe with sprayed silicone, or a plastic resin syringe that does not contain silicone. (Item 30) 28. The container of item 27, wherein the stable formulation is present in a volume of less than about 5.0 mL. (Item 31) 28. The container of item 27, wherein the stable formulation is present in a volume of less than about 3.0 mL. (Item 32) 1. A method for treating Hunter syndrome, comprising: A method comprising a step of intrathecally administering to a subject in need of treatment a stable formulation according to any one of items 1 to 20. (Item 33) 1. A method for treating Hunter syndrome, comprising: 1. A method comprising the step of intrathecally administering to a subject in need of treatment a stable formulation comprising iduronate-2-sulfatase (I2S) protein at a concentration ranging from about 1 to 300 mg / ml, NaCl at a concentration of about 154 mM, polysorbate 20 at a concentration of about 0.005%, and a pH of about 6. (Item 34) 34. The method of claim 32 or 33, wherein the intrathecal administering step does not cause substantial adverse events in the subject. (Item 35) 35. The method of claim 34, wherein said intrathecal administration does not result in a substantial adaptive T cell-mediated immune response in said subject. (Item 36) 36. The method of any one of items 32 to 35, wherein the intrathecal administration of the formulation results in delivery of the I2S protein to a target brain tissue. (Item 37) 37. The method of claim 36, wherein the brain target tissue comprises neurons within white matter and / or gray matter. (Item 38) 38. The method of claim 36 or 37, wherein the I2S protein is delivered to neurons, glial cells, perivascular cells and / or meningeal cells. (Item 39) 40. The method of any one of items 37 to 39, wherein the I2S protein is further delivered to neurons in the spinal cord. (Item 40) 40. The method of any one of items 37 to 39, wherein the intrathecal administration of the formulation further results in systemic delivery of the I2S protein in a peripheral target tissue. (Item 41) 34. The method of claim 33, wherein the peripheral target tissue is selected from the liver, kidney, and / or heart. (Item 42) 42. The method according to any one of items 32 to 41, wherein said intrathecal administration of said formulation results in lysosomal localization in brain target tissues, spinal cord neurons and / or peripheral target tissues. (Item 43) 43. The method of any one of items 32 to 42, wherein the intrathecal administration of the formulation reduces GAG accumulation in the brain target tissue, spinal cord neurons and / or peripheral target tissue. (Item 44) 44. The method of claim 43, wherein the GAG ​​accumulation is reduced by at least 20%, 40%, 50%, 60%, 80%, 90%, 1-fold, 1.5-fold, or 2-fold compared to a control. (Item 45) 45. The method of any one of items 32 to 44, wherein said intrathecal administration of said formulation reduces vacuolization in neurons. (Item 46) 46. ​​The method of claim 45, wherein the neuron comprises a Purkinje cell. (Item 47) 36. The method of any one of items 32 to 35, wherein the intrathecal administration of the formulation results in an increase in I2S enzyme activity in the brain target cells, spinal cord neurons and / or peripheral target tissues. (Item 48) 48. The method of claim 47, wherein the I2S enzyme activity is increased by at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or 10-fold compared to a control. (Item 49) 49. The method of item 47 or 48, wherein the increase in I2S enzyme activity is at least about 10 nmol / hr·mg, 20 nmol / hr·mg, 40 nmol / hr·mg, 50 nmol / hr·mg, 60 nmol / hr·mg, 70 nmol / hr·mg, 80 nmol / hr·mg, 90 nmol / hr·mg, 100 nmol / hr·mg, 150 nmol / hr·mg, 200 nmol / hr·mg, 250 nmol / hr·mg, 300 nmol / hr·mg, 350 nmol / hr·mg, 400 nmol / hr·mg, 450 nmol / hr·mg, 500 nmol / hr·mg, 550 nmol / hr·mg or 600 nmol / hr·mg. (Item 50) 48. The method of claim 47, wherein the I2S enzyme activity is increased in the lumbar region. (Item 51) 51. The method of claim 50, wherein the increase in I2S enzyme activity in the lumbar region is at least about 2000 nmol / hr·mg, 3000 nmol / hr·mg, 4000 nmol / hr·mg, 5000 nmol / hr·mg, 6000 nmol / hr·mg, 7000 nmol / hr·mg, 8000 nmol / hr·mg, 9000 nmol / hr·mg, or 10,000 nmol / hr·mg. (Item 52) 52. The method of any one of items 32-51, wherein said intrathecal administration of said formulation results in a reduction in the intensity, severity or frequency of, as well as a delay in the onset of, at least one symptom or feature of Hunter Syndrome. (Item 53) 33. The method of claim 32, wherein at least one of the symptoms or characteristics of Hunter syndrome is cognitive impairment; white matter lesions; dilated perivascular spaces in the brain parenchyma, corpus callosum, ganglia, and / or brain stem; and / or ventricular enlargement. (Item 54) 52. The method according to any one of items 32 to 51, wherein the intrathecal administration is performed once every two weeks. (Item 55) 52. The method according to any one of items 32 to 51, wherein the intrathecal administration is performed once a month. (Item 56) 52. The method according to any one of items 32 to 51, wherein the intrathecal administration is performed once every two months. (Item 57) 57. The method according to any one of items 32 to 56, wherein the intrathecal administration is used in conjunction with intravenous administration. (Item 58) 58. The method of item 57, wherein the intravenous administration is no more frequent than once a month. (Item 59) 58. The method of item 57, wherein the intravenous administration is no more frequent than once every two months. (Item 60) 57. The method according to items 32 to 56, wherein the intrathecal administration is used in the absence of intravenous administration. (Item 61) 61. The method according to items 32 to 60, wherein the intrathecal administration is used in the absence of concomitant immunosuppressive therapy. [Brief description of the drawings]

[0035] [Figure 1] Illustrative diagram showing IT delivered I2S detected in neurons (arrows) of the cerebral and cerebellar cortex containing I2S within the layer of meningeal cells (arrowheads) covering the surface of the brain after intrathecal injection of three doses of I2S. I2S IHC staining in two-dose injected brains was weaker (photo not shown). No positive I2S staining was observed for any type of cell in the brains of vehicle control animals. (40X) [Diagram 2]Illustrative diagram showing reversal of lesions in the brain of I2S knockout (IKO) mice after intrathecal-lumbar I2S injection. H&E stained brain tissue showed numerous intracellular storage vacuoles (arrows) in vehicle control animals. Intracellular vacuolization was reduced throughout the brain in both 2-dose (photo not shown) and 3-dose injected mice. A significant reduction was seen in 3-dose injected mice. (40X) [Diagram 3] Illustrative diagram showing immunohistochemical staining for LAMP-1, where there is a significant reduction in lysosomal activity in the brain following 2 doses (photo not shown) and 3 doses of I2S treatment compared to vehicle control mice. This reduction was characterized by a decrease in the number of LAMP-1 positive cells and brighter staining intensity in regions throughout the brain. (40X) [Figure 4] Exemplary figures showing morphometric results from comparison of mean LAMP-1 positive areas in the cerebral cortex (Cortex), caudate nucleus (CP), thalamus (TH), white matter (WM) and cerebellum (CBL) among wild-type (WT), vehicle untreated and I2S (2 and 3 doses) mice, confirming a significant reduction in LAMP-1 positive staining in all brain regions evaluated. Data are presented as mean ± standard deviation, #P<0.05; *P<0.01; **P<0.001. [Diagram 5] Exemplary electron micrographs of brain cells showing lesion amelioration at the ultrastructural level. Neurons from vehicle-treated mice had disc-shaped inclusions, zebra body-like structures, and vacuoles containing granular storage material (inserts), which were reduced in I2S-injected mice. Oligodendrocytes from vehicle-treated mice showed large electronlucent storage vacuoles (arrows), whereas I2S-injected mice had minimal vacuoles. (Scale bars: in neurons, 2 μm; in oligodendrocytes, 500 nm) [Figure 6] Exemplary immunohistochemistry results showing I2S detected within liver sinusoidal cells after intrathecal injection of three doses of I2S. I2S IHC staining in two-dose injected livers was weaker (photo not shown). There was no positive I2S staining in the livers of vehicle control animals. (40X) [Figure 7] Exemplary tissue from the liver is shown. Severe cellular vacuolization and abnormally high lysosomal activity were noted by H&E staining, with strong LAMP-1 immunostaining found in vehicle control animals compared to WT animals. A significant reduction in intracellular vacuolization and LAMP-1 immunostaining was confirmed after intrathecal treatment with 3 and 2 doses of I2S treatment (photos not shown). H&E staining showed that intracytoplasmic vacuolization was almost completely absent, with nearly normal liver cell structure. (H&E, 40X; LAMP-1, 20X) [Figure 8-1] Exemplary data comparing aggregation by SEC-HPLC for saline and phosphate formulations (all containing 0.01% polysorbate-20): at <-65°C and 40°C for 1 month is shown. [Figure 8-2] Exemplary data comparing aggregation by SEC-HPLC for saline and phosphate formulations (all containing 0.01% polysorbate-20): at ≦−65° C. and 40° C. for 1 month is shown. [Figure 9-1] Exemplary data comparing aggregation by SEC-HPLC for saline and phosphate formulations (all containing 0.01% polysorbate-20): ≦−65° C. and 25° C. for 6 months is shown. [Figure 9-2] Exemplary data comparing aggregation by SEC-HPLC for saline and phosphate formulations (all containing 0.01% polysorbate-20): at ≦−65° C. and 25° C. for 6 months is shown. [Figure 10-1] Exemplary data are shown comparing aggregation by SEC-HPLC for saline and phosphate formulations (all containing 0.01% polysorbate-20): at <-65°C and 2-8°C for 24 months. [Figure 10-2] Exemplary data are presented comparing aggregation by SEC-HPLC for saline and phosphate formulations (all containing 0.01% polysorbate-20): at ≦-65°C and 2-8°C for 24 months. [Figure 11-1]Exemplary data comparing saline and phosphate formulations (all containing 0.01% polysorbate-20): baseline vs. 1 month at 40° C. by SAX-HPLC method are shown. [Figure 11-2] Exemplary data comparing saline and phosphate formulations (all containing 0.01% polysorbate-20): baseline versus 1 month at 40° C., change by SAX-HPLC method is shown. [Figure 12-1] Exemplary data comparing saline and phosphate formulations (all containing 0.01% polysorbate-20): baseline versus 6 months at 25° C. by SAX-HPLC method are shown. [Figure 12-2] Exemplary data comparing saline and phosphate formulations (all containing 0.01% polysorbate-20): baseline versus 6 months at 25° C., change by SAX-HPLC method is shown. [Figure 13-1] Exemplary data comparing saline and phosphate formulations (all containing 0.01% polysorbate-20): baseline versus 24 months at 2-8° C., change by SAX-HPLC method is shown. [Figure 13-2] Exemplary data comparing saline and phosphate formulations (all containing 0.01% polysorbate-20): baseline versus 24 months at 2-8°C, change by SAX-HPLC method is shown. [Figure 14] Exemplary data comparing saline and phosphate formulations (all containing 0.01% polysorbate-20): SDS-PAGE, Coomassie staining at baseline and 1 month at 40° C. are shown. [Figure 15A] Exemplary data are shown comparing SDS-PAGE, Coomassie staining for saline and phosphate formulations (all containing 0.01% polysorbate-20): 6 months at 25° C. and over 16 months at 2-8° C. [Figure 15B]Exemplary data are shown comparing SDS-PAGE, Coomassie staining for saline and phosphate formulations (all containing 0.01% polysorbate-20): 6 months at 25° C. and over 16 months at 2-8° C. [Figure 16] An exemplary histology showing the cerebrum of a 3 mg treatment animal is shown. Positive I2S staining was observed within meningeal cells. (4X) [Figure 17] An exemplary tissue showing the cerebrum of a 30 mg treatment animal is shown. Positive I2S staining was observed in neurons and meningeal cells. (4X) [Figure 18] An exemplary tissue showing the cerebrum of a 100 mg treated animal is shown. Positive I2S staining neurons and meningeal cells were more intense than those of the 3 and 30 mg treated animals. (4X) [Figure 19] An exemplary tissue showing the cerebrum of a 150 mg treatment animal is shown. A large population of neurons were 12S positive along with strongly positive meningeal cells. [Figure 20] Representative histology showing I2S positive neurons and glial cells along with meningeal cells in layer III of the cerebrum in a 30 mg treated animal (40X). [Figure 21] Representative histology showing I2S positive neurons, glial cells along with perivascular cells in layer III of the cerebrum in a 30 mg treated animal (40X). [Figure 22] Representative histology showing I2S positive neurons and glial cells in layer VI of the cerebrum adjacent to the white matter in a 30 mg treated animal (40X). [Figure 23] An exemplary tissue showing strong positive I2S staining within neurons (cerebrum) from a 150 mg treatment animal is shown (100X). [Figure 24] 13 is an exemplary histology showing I2S immunostaining of the cervical spinal cord from 150 mg treatment animals. (4X) [Diagram 25] Representative tissue showing strong I2S immunostaining in the lumbar spinal cord of a 150 mg treatment animal. (4X) [Figure 26]Exemplary tissue showing strongly positive I2S immunostaining of meningeal cells, glial cells, and epi / peri / intrinsic sheaths (connective cells) was found in the lumbar region of 150 mg treated animals (40X). [Figure 27] Neurons in the lumbar spinal cord of animals treated with 150 mg were strongly I2S positive (40X). [Figure 28] Exemplary results from livers from 3 mg treated animals are shown. Only sinusoidal cells were I2S positive. (40X) [Figure 29] Exemplary results from livers from 30 mg treated animals are shown. Sinusoidal and hepatic cells were I2S positive. (40X) [Diagram 30] Exemplary results from livers from 100 mg treatment animals are shown. I2S immunostaining was very strong in sinusoidal and hepatic cells. (40X) [Diagram 31] Exemplary results from livers from 150 mg treatment animals are shown. Strongly positive I2S staining was identified in sinusoidal and hepatocytes. (40X) [Diagram 32] Exemplary results from hearts from 3 mg treated animals are shown. I2S immunostaining was negative. (40X) [Diagram 33] Exemplary results from hearts from 30 mg treated animals are shown. Interstitial cells were I2S positive. (40X) [Diagram 34] FIG. 1 shows exemplary results from hearts from 100 mg treatment animals. Interstitial cell staining was positive for I2S. (40X) [Diagram 35] Exemplary results from hearts from 150 mg treatment animals are shown. Interstitial cell staining was strongly positive for I2S. (40X) [Diagram 36] FIG. 13 shows exemplary results from kidneys from 3 mg treatment animals. I2S immunostaining was negative. (40X) [Figure 37] Exemplary results from kidneys from 30 mg treatment animals are shown. Glomerular and interstitial cells were I2S positive. [Figure 38]Exemplary results from kidneys from 100 mg treated animals are shown. Increased staining of glomerular and interstitial cells for I2S was observed. (40X) [Figure 39] Exemplary results from kidneys from 150 mg treated animals are shown. Positive I2S staining of proximal tubule, glomerular and interstitial cells was observed. (40X) [Diagram 40] Figure 40 shows the results of immunohistochemistry (IHC) studies evaluating CNS tissues of cynomolgus monkeys administered weekly doses of iduronate-2-sulfatase (I2S). There was widespread cellular deposition of I2S throughout the CNS as determined by IHC. In the gray matter, I2S was detected in neurons of the cerebrum, cerebellum, brainstem, and spinal cord in all groups in a dose-dependent manner. In the superficial gray matter of the high-dose group, the majority of intracranial neurons were positive for I2S in the superficial cortex (Figure 40A). I2S was also detected in the thalamus (Figure 40B), hippocampus (Figure 40C), caudate nucleus (Figure 40D), and spinal cord (Figure 40E). Meningeal and perivascular cells also stained positive for I2S (Figure 40F). The indicated scale bar corresponds to 25 μm. [Diagram 41] The excretion of iduronate-2-sulfatase (I2S) in the cranial and spinal pools is compared graphically by plotting the amount of I2S in the cranial and spinal pools versus time after administration. [Diagram 42] Dose-dependent gray matter deposition of iduronate-2-sulfatase (I2S) administered intrathecally to non-human primates over a 6-month period. The staining intensity shown corresponds to the accumulation of iduronate-2-sulfatase in the thalamus. In this Figure 42, nuclei are counterstained with DAPI and appear in blue, and protein (I2S) appears in green. [Diagram 43] FIG. 1 shows dose-dependent grey matter deposition of intrathecally administered iduronate-2-sulfatase (I2S) in non-human primates after a single injection and multiple injections over a 6-month period. The staining intensity shown corresponds to accumulation of iduronate-2-sulfatase in the cerebral cortex. [Diagram 44]We demonstrate the subcellular localization of iduronate-2-sulfatase (I2S) throughout the non-human primate cerebrum. Figure 44A shows a cross-section of brain tissue extracted from the non-human primate cerebrum, while Figure 44B shows three regions of white matter tissue (designated W1, W2 and W3) of the section identified in Figure 44A, specific regions corresponding to the periventricular white matter (VW) and superficial gray matter (SG) tissue. [Figure 45-1] Neuronal and oligodendrocyte uptake and axonal association of intrathecally administered iduronate-2-sulfatase (I2S) in non-human primates after monthly injections over a six-month period. In particular, Figure 45A, Figure 45B, Figure 45C, and Figure 45D show filament staining of cerebral tissue from non-human primates administered intrathecally with iduronate-2-sulfatase (I2S), corresponding to the three regions of white matter (W1, W2, and W3) and the superficial gray matter (SG) region identified in Figure 44B, respectively. Figure 45A shows oligodendrocyte uptake of intrathecally administered I2S in white matter (W1) tissue. Figure 45B and Figure 45C show oligodendrocyte uptake and axonal association of intrathecally administered I2S in W2 and W3 white matter tissue, respectively. FIG. 45D shows neuronal uptake of intrathecally administered I2S in superficial gray matter (SG) tissue. [Figure 45-2] FIG. 45A shows the neuronal and oligodendrocyte uptake and axonal association of intrathecally administered iduronate-2-sulfatase (I2S) in non-human primates after monthly injections over a six-month period. In particular, FIG. 45A, FIG. 45B, FIG. 45C, and FIG. 45D show filament staining of cerebral tissue from non-human primates administered intrathecally with iduronate-2-sulfatase (I2S), corresponding to the three regions of white matter (W1, W2, and W3) and the superficial gray matter (SG) region identified in FIG. 44B, respectively. FIG. 45A shows the oligodendrocyte uptake of intrathecally administered I2S in white matter (W1) tissue. FIG. 45B and FIG. 45C show the oligodendrocyte uptake and axonal association of intrathecally administered I2S in W2 and W3 white matter tissue, respectively. FIG. 45D shows neuronal uptake of intrathecally administered I2S in superficial gray matter (SG) tissue. [Figure 46]Figure 46 shows the intracellular identification of iduronate-2-sulfatase in the periventricular white matter (VW) of non-human primates. As shown in the supplementary image, iduronate-2-sulfatase is not associated with myelin (red). In our FIG. 46, nuclei are counterstained with DAPI (lower left). The protein (I2S) appears in the upper left box. [Figure 47] Figures 47A-47H show staining in tissues of healthy beagle dogs administered a single injection of iduronate-2-sulfatase (I2S) intracerebroventricularly (ICV) or intrathecally (IT). As shown in Figures 47A-47H, I2S was distributed widely throughout the gray matter in both IT and ICV groups, as determined by immunohistochemistry (IHC). Figures 47A and 47B show that in the cerebral cortex, neurons were positive for I2S in all six neuronal layers, from the superficial molecular layer to the deep internal layer in both IT and ICV groups. Figures 47C and 47D show that in the cerebellar cortex in IT and ICV groups, I2S was detected in neurons, including Purkinje cells. Similarly, Figures 47E and 47F show that a large population of neurons in the hippocampus was positive for I2S in both IT and ICV groups. Finally, images g and h demonstrate that I2S-positive neurons were also found in the thalamus and caudate nucleus in both the IT and ICV groups. In FIG. 47 of the present invention, I2S staining is indicated by arrows. [Figure 48] A comparison of corpus callosum tissue from iduronate-2-sulfatase knockout (IKO) mice that were either untreated or administered I2S intrathecally is shown. As shown, treated IKO mice exhibited reduced intracellular vacuolization, a hallmark of certain lysosomal storage disorders, in the corpus callosum and fornix tissue of I2S-treated IKO mice. [Figure 49A] Figure 93A shows a significant reduction in the presence of lysosomal disease pathology biomarker lysosomal associated membrane protein 1 (LAMP-1) in the superficial cerebral cortex tissue of treated IKO mice (Figure 49A) compared to untreated IKO control mice (Figure 49B). Magnifications 20x and 40x. [Figure 49B]Figure 93A shows a significant reduction in the presence of lysosomal disease pathology biomarker lysosomal associated membrane protein 1 (LAMP-1) in the superficial cerebral cortex tissue of treated IKO mice (Figure 49A) compared to untreated IKO control mice (Figure 49B). Magnifications 20x and 40x. [Figure 50] 1 illustrates an exemplary intrathecal drug delivery device (IDDD). [Figure 51] 1 illustrates an exemplary PORT-A-CATH® low profile intrathecal implantable access system. [Figure 52] 1 illustrates an exemplary intrathecal drug delivery device (IDDD). [Diagram 53] An intrathecal drug delivery device (IDDD) is shown, enabling home administration for CNS enzyme replacement therapy (ERT). [Figure 54] FIG. 1 shows an exemplary effect of vacuolization after a single intracerebral injection of idursulfase in neurons (Purkinje cells). [Figure 55] FIG. 1 is an illustrative diagram showing I2S activity in the brain by dose and region. [Figure 56] FIG. 1 is an illustrative diagram showing immunohistochemical localization data of idursulfase at different depths in the cerebral cortex. [Figure 57] FIG. 1 is an illustration showing I2S activity in the spinal cord of monkeys after intrathecal dose administration of idursulfase. [Figure 58] FIG. 1 is an illustrative diagram showing I2S activity in monkey liver, heart and kidney after an intrathecal dose of idursulfase. [Figure 59] 1 depicts an exemplary schematic diagram for an expanded Hunter IT testing program. [Figure 60] 1 is an illustrative diagram showing the measurement of I2S concentration in different sections of brain tissue after a 30 mg dose, with different plots corresponding to different measurement times. [Figure 61] FIG. 13 is an illustrative diagram showing measured I2S concentrations after prolonged administration via various routes of administration for various product concentrations. [Figure 62]FIG. 1 illustrates PET images of 124I-labeled idursulfase-IT in cynomolgus monkeys at t=5 hours after administration of an IV, IT-L or ICV dose. [Figure 63] FIG. 1 is an exemplary diagram of an intrathecal drug delivery device IDDD. [Fig. 64A] Various features of IDDD are shown both in the subject's body (FIG. 64A) and in a planar view (FIG. 64B). [Figure 64B] Various features of IDDD are shown both in the subject's body (FIG. 64A) and in a planar view (FIG. 64B). [Fig. 64C] Various features of IDDD are shown both in the subject's body (FIG. 64A) and in a planar view (FIG. 64B). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0036] definition In order that the present invention may be more readily understood, certain terms are first defined below. Additional definitions for the following terms, as well as other terms, are set forth throughout the specification.

[0037] "Approximately or about": As used herein, the term "approximately" or "about" when applied to one or more of the values ​​in question refers to a value similar to the stated reference value. In one embodiment, the term "approximately" or "about" refers to a set of values ​​that are within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction of the stated reference value, unless otherwise stated or otherwise apparent from the context (except where such number exceeds 100% of possible values).

[0038] "Amelioration": As used herein, the term "amelioration" refers to the prevention, reduction or alleviation of a condition, or the improvement of a subject's condition. Amelioration includes, but does not require, complete recovery or complete prevention of a disease condition. In some embodiments, amelioration includes increased levels of the associated protein or its activity that is lacking in the associated diseased tissue.

[0039] "Biologically active": As used herein, the phrase "biologically active" refers to a characteristic of any agent that has activity in a biological system, particularly in an organism. For example, an agent that has a biological effect on an organism when administered to the organism is considered to be biologically active. In certain embodiments in which a protein or polypeptide is biologically active, a portion of the protein or polypeptide that shares at least one biological activity of the protein or polypeptide is typically referred to as a "biologically active" portion.

[0040] "Bulking Agent": As used herein, the term "bulking agent" refers to a compound that adds mass to a lyophilization mixture and contributes to the physical structure of the lyophilized cake (e.g., promotes the production of an essentially uniform lyophilized cake that retains its open structure). Examples of bulking agents include mannitol, glycine, sodium chloride, hydroxyethyl starch, lactose, sucrose, trehalose, polyethylene glycol, and dextran.

[0041] "Cation-independent mannose-6-phosphate receptor (CI-MPR)": As used herein, the term "cation-independent mannose-6-phosphate receptor (CI-MPR)" refers to a cellular receptor that binds the mannose-6-phosphate (M6P) tag on acid hydrolases in the Golgi apparatus that are destined for transport to lysosomes. In addition to mannose-6-phosphate, CI-MPR also binds other proteins, such as IGF-II. CI-MPR is also known as "M6P / IGF-II receptor", "CI-MPR / IGF-II receptor", "IGF-II receptor" or "IGF2 receptor". These terms and their abbreviations are used interchangeably herein.

[0042] "Concomitant immunosuppressant therapy": As used herein, the term "concomitant immunosuppressant therapy" includes any immunosuppressant therapy used as pretreatment, preconditioning, or in parallel with a treatment method.

[0043] "Diluent": As used herein, the term "diluent" refers to a pharma- ceutically acceptable (e.g., safe and non-toxic for human administration) diluent substance useful for preparing a reconstituted formulation. Examples of diluents include sterile water, bacteriostatic water for injection (BWFI), pH buffered solutions (e.g., phosphate buffered saline), sterile saline solution, Ringer's solution, or dextrose solution.

[0044] "Dosage form": As used herein, the terms "dosage form" and "unit dosage form" refer to a physically discrete unit of therapeutic protein for the patient to be treated. Each unit contains a predetermined amount of active material calculated to produce the desired therapeutic effect. It will be understood, however, that the total amount of the composition to be administered will be determined by the attending physician within the scope of sound medical judgment.

[0045] "Enzyme Replacement Therapy (ERT)": As used herein, the term "enzyme replacement therapy (ERT)" refers to any therapeutic strategy that corrects an enzyme deficiency by providing the missing enzyme. In some embodiments, the missing enzyme is provided by intrathecal administration. In some embodiments, the missing enzyme is provided by injection into the bloodstream. Once administered, the enzyme is taken up by the cell and transported to the lysosomes where it acts to remove material that has accumulated in the lysosomes due to the enzyme deficiency. Typically, for lysosomal enzyme replacement therapy to be effective, the therapeutic enzyme is delivered to the lysosomes in the appropriate cells in the target tissue where the storage defect is manifest.

[0046] "Improve, increase or reduce": As used herein, the terms "improve," "increase" or "reduce," or grammatical equivalents, refer to a value as compared to a baseline measurement, e.g., a measurement in the same individual prior to the initiation of a treatment described herein, or a measurement in a control individual (or multiple control individuals) in the absence of a treatment described herein. A "control individual" is an individual suffering from the same type of lysosomal storage disease as the individual being treated and who is approximately the same age as the individual being treated (to ensure that the stage of the disease in the treated and control individual(s) is comparable).

[0047] "Individual, subject, patient": As used herein, the terms "subject", "individual" or "patient" refer to a human or non-human mammalian subject. The individual being treated (also referred to as a "patient" or "subject") is an individual (fetus, infant, child, adolescent or adult) suffering from a disease.

[0048] "Intrathecal administration": As used herein, the term "intraceal administration" or "intraceal injection" refers to an injection into the spinal canal (the intrathecal space surrounding the spinal cord). Various techniques may be used, including but not limited to lateral ventricular injection through a burr hole or cisterna or lumbar puncture. In some embodiments, "intraceal administration" or "intraceal delivery" according to the present invention refers to IT administration or delivery via the lumbar region or area, i.e., lumbar IT administration or delivery. As used herein, the term "lumbar region" or "lumbar region" refers to the area between the third and fourth lumbar vertebrae (low back), more generally, the L2-S1 region of the spine.

[0049] "Linker": As used herein, the term "linker" refers to an amino acid sequence in a fusion protein other than that which occurs at a specific position in the native protein, and is generally intended to be flexible or to interpose a structure, such as a helix, between two protein moieties. Linkers are also referred to as spacers.

[0050] "Lyoprotectant": As used herein, the term "lyoprotectant" refers to a molecule that prevents or reduces the chemical and / or physical instability of proteins or other substances during lyophilization and subsequent storage. Examples of lyoprotectants include sugars, such as sucrose or trehalose; amino acids, such as glutamic acid or monosodium histidine; methylamines, such as betaine; lyotropic salts, such as magnesium sulfate; polyols, such as trihydric or higher sugar alcohols, such as glycerin, erythritol, glycerol, arabitol, xylitol, sorbitol and mannitol; propylene glycol; polyethylene glycol; pluronics; and combinations thereof. In some embodiments, the lyoprotectant is a non-reducing sugar, such as trehalose or sucrose.

[0051] "Lysosomal enzyme": As used herein, the term "lysosomal enzyme" refers to any enzyme that can reduce stored materials in mammalian lysosomes or rescue or ameliorate one or more lysosomal storage disease symptoms. Lysosomal enzymes suitable for the present invention include both wild-type or modified lysosomal enzymes and can be produced using recombinant and synthetic methods or purified from natural sources. Examples of lysosomal enzymes are listed in Table 1.

[0052] "Lysosomal enzyme deficiency": As used herein, "lysosomal enzyme deficiency" refers to a group of genetic disorders resulting from a deficiency in at least one of the enzymes required to break down macromolecular substances (e.g., enzyme substrates) in the lysosome into peptides, amino acids, monosaccharides, nucleic acids, and fatty acids. As a result, individuals suffering from lysosomal enzyme deficiency accumulate substances in various tissues (e.g., CNS, liver, spleen, intestine, blood vessel walls, and other organs).

[0053] "Lysosomal storage disease": As used herein, the term "lysosomal storage disease" refers to any disease resulting from a deficiency of one or more lysosomal enzymes required to metabolize natural polymeric substances. These diseases typically result in the accumulation of non-degraded molecules in lysosomes, leading to an increase in the number of storage granules (also called storage vesicles). These diseases and various examples are described in detail below.

[0054] "Polypeptide": As used herein, a "polypeptide" is generally a string of at least two amino acids joined together by peptide bonds. In some embodiments, a polypeptide may contain at least 3-5 amino acids, each of which is joined to the others by at least one peptide bond. Those of skill in the art will appreciate that polypeptides sometimes include "unnatural" amino acids or other entities that may still optionally be incorporated into a polypeptide chain.

[0055] "Replacement enzyme": As used herein, the term "replacement enzyme" refers to any enzyme that can act to at least partially replace an enzyme that is deficient or missing in a disease to be treated. In some embodiments, the term "replacement enzyme" refers to any enzyme that can act to at least partially replace a lysosomal enzyme that is deficient or missing in a lysosomal storage disease to be treated. In some embodiments, the replacement enzyme can reduce stored material in mammalian lysosomes or rescue or ameliorate one or more lysosomal storage disease symptoms. Replacement enzymes suitable for the present invention include both wild-type or modified lysosomal enzymes and can be produced using recombinant and synthetic methods or purified from natural sources. Replacement enzymes can be recombinant, synthetic, gene-activated, or natural enzymes.

[0056] "Soluble": As used herein, the term "soluble" refers to the ability of a therapeutic agent to form a homogenous solution. In some embodiments, the solubility of a therapeutic agent in the solution in which it is administered and in which it is transported to the target site of action (e.g., cells and tissues of the brain) is sufficient to allow delivery of a therapeutically effective amount of the therapeutic agent to the target site of action. Several factors may affect the solubility of a therapeutic agent. For example, relevant factors that may affect protein solubility include ionic strength, amino acid sequence, and the presence of other co-solubilizing agents or salts (e.g., calcium salts). In some embodiments, pharmaceutical compositions are formulated such that calcium salts are removed from such compositions. In some embodiments, a therapeutic agent according to the present invention is soluble in its corresponding pharmaceutical composition. Although isotonic solutions are generally preferred for parenterally administered drugs, it is understood that the use of isotonic solutions may limit the appropriate solubility of some therapeutic agents, particularly some proteins and / or enzymes. Slightly hypertonic solutions (e.g., up to 175 mM sodium chloride in 5 mM sodium phosphate, pH 7.0) and sugar-containing solutions (e.g., up to 2% sucrose in 5 mM sodium phosphate, pH 7.0) have been demonstrated to be well tolerated in monkeys. For example, the most commonly approved CNS bolus formulation composition is saline (150 mM NaCl in water).

[0057] "Stability": As used herein, the term "stable" refers to the ability of a therapeutic agent (e.g., a recombinant enzyme) to retain its therapeutic efficacy (e.g., all or a majority of its intended biological activity and / or physicochemical integrity) over an extended period of time. The stability of a therapeutic agent, as well as the ability of a pharmaceutical composition to retain such stability of a therapeutic agent, can be assessed over an extended period of time (e.g., at least 1, 3, 6, 12, 18, 24, 30, 36 months or more). Generally, the pharmaceutical compositions described herein are formulated such that they can stabilize, or slow or prevent the degradation of, one or more therapeutic agents (e.g., recombinant proteins) with which they are formulated. In the context of a formulation, a stable formulation is one in which the therapeutic agent therein essentially retains its physical and / or chemical integrity and biological activity during storage and processing (e.g., freeze / thaw, mechanical mixing and lyophilization). With respect to protein stability, it can be measured by the formation of high molecular weight (HMW) aggregates, loss of enzymatic activity, generation of peptide fragments, and shifts in charge profile.

[0058] "Subject": As used herein, the term "subject" refers to any mammal, including a human. In certain embodiments of the invention, the subject is an adult, an adolescent, or a child. Administration of pharmaceutical compositions and / or performance of in utero therapeutic methods are also contemplated by the present invention.

[0059] "Substantial homology": The phrase "substantial homology" is used herein to refer to a comparison between amino acid or nucleic acid sequences. As will be understood by those skilled in the art, two sequences are generally considered to be "substantially homologous" if they contain homologous residues at corresponding positions. Homologous residues can be identical residues. Alternatively, homologous residues can be non-identical residues that have roughly similar structural and / or functional characteristics. For example, as is well known to those skilled in the art, certain amino acids are typically classified as "hydrophobic" or "hydrophilic" amino acids and / or as having "polar" or "non-polar" side chains. Substitution of one amino acid with another amino acid of the same type can often be considered a "homologous" substitution.

[0060] As is well known in the art, amino acid or nucleic acid sequences can be compared using various algorithms, such as commercially available computer programs, such as BLASTN for nucleotide sequences, and BLASTP, gapped BLAST and PSI-BLAST for amino acid sequences. Examples of such programs include Altschul, et al., Basic local alignment search tool, J. Mol. Biol., 215(3): 403-410, 1990;Altschul, et al., Methods in Enzymology; Altschul, et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402, 1997;Baxevanis, et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press, 1999. In addition to identifying homologous sequences, the above programs typically provide an indication of the degree of homology. In some embodiments, two sequences are considered to be substantially homologous if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are homologous over the related strand of residues. In some embodiments, the related strand is a complete sequence. In some embodiments the associated strand is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more residues.

[0061] "Substantial identity": The phrase "substantial identity" is used herein to refer to a comparison between amino acid or nucleic acid sequences. As will be understood by those skilled in the art, two sequences are generally considered to be "substantially identical" if they contain identical residues at corresponding positions. As is well known in the art, amino acid or nucleic acid sequences can be compared using various algorithms, such as commercially available computer programs, such as BLASTN for nucleotide sequences, and BLASTP, gapped BLAST and PSI-BLAST for amino acid sequences. Examples of such programs include Altschul, et al., Basic local alignment search tool, J. Mol. Biol., 215(3): 403-410, 1990;Altschul, et al., Methods in Enzymology; Altschul, et al., Nucleic Acids Res. 25:3389-3402, 1997;Baxevanis, et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press, 1999. In addition to identifying identical sequences, the above programs typically provide an indication of the degree of identity. In some embodiments, two sequences are considered to be substantially identical if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of their corresponding residues are identical over the relevant strand of residues. In some embodiments, the relevant strand is a complete sequence. In some embodiments the associated strand is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more residues.

[0062] "Synthetic CSF": As used herein, the term "synthetic CSF" refers to a solution that has a pH, electrolyte composition, glucose content and osmolality that is consistent with cerebrospinal fluid. Synthetic CSF is also referred to as artificial CSF. In some embodiments, the synthetic CSF is Elliot's B solution.

[0063] "Suitable for CNS delivery": As used herein, the phrases "suitable for CNS delivery" or "suitable for intrathecal delivery", as it relates to pharmaceutical compositions of the invention, generally refer to the stability, tolerability and solubility properties of such compositions, as well as the ability of such compositions to deliver an effective amount of a therapeutic agent contained therein to a targeted delivery site (e.g., CSF or brain).

[0064] "Target tissue": As used herein, "target tissue" refers to any tissue affected by the lysosomal storage disease to be treated or any tissue in which the deficient lysosomal enzyme is normally expressed. In some embodiments, the target tissue includes tissues in which detectable or abnormally high amounts of enzyme substrates are present, e.g., stored in the cellular lysosomes of the tissue, in patients suffering from or susceptible to lysosomal storage disease. In some embodiments, the target tissue includes tissues that exhibit disease-related pathology, symptoms, or characteristics. In some embodiments, the target tissue includes tissues in which the deficient lysosomal enzyme is normally expressed at high levels. As used herein, the target tissue may be a brain target tissue, a spinal cord target tissue, and / or a peripheral target tissue. Examples of target tissues are described in detail below.

[0065] "Therapeutic moiety": As used herein, the term "therapeutic moiety" refers to a portion of a molecule that performs the therapeutic function of the molecule. In some embodiments, a therapeutic moiety is a polypeptide having therapeutic activity.

[0066] "Therapeutically effective amount": As used herein, the term "therapeutically effective amount" refers to an amount of a therapeutic protein (e.g., replacement enzyme) that confers a therapeutic effect on the treated subject at a reasonable benefit / risk ratio applicable to any medical treatment. The therapeutic effect can be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject gives an indication of or feels the effect). In particular, "therapeutically effective amount" refers to an amount of a therapeutic protein or composition effective to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or prophylactic effect, for example, by improving symptoms associated with the disease, preventing or delaying the onset of the disease, and / or reducing the severity or frequency of symptoms of the disease. Therapeutically effective amounts are generally administered in a dosage administration regimen that may include multiple unit doses. For any particular therapeutic protein, the therapeutically effective amount (and / or the appropriate unit dose within an effective dosage administration regimen) may vary, for example, depending on the route of administration, combination with other pharmaceutical agents. Furthermore, the specific therapeutically effective amount (and / or unit dose) for any particular patient will depend on a variety of factors, such as the disorder being treated, and the severity of the disorder; the activity of the specific pharmaceutical agent used; the specific composition used; the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration, and / or rate of excretion or metabolism of the specific fusion protein used; the duration of treatment; and similar factors as are well known in the medical arts.

[0067] "Tolerable": As used herein, the terms "tolerable" and "tolerability" refer to the ability of the pharmaceutical compositions of the invention to not elicit an adverse reaction in a subject to which such composition is administered, or alternatively, to not elicit a severe adverse reaction in a subject to which such composition is administered. In some embodiments, the pharmaceutical compositions of the invention are well tolerated by the subject to which such composition is administered.

[0068] "Treatment": As used herein, the term "treatment" (also referred to as "treat" or "treating") refers to any administration of a therapeutic protein (e.g., a lysosomal enzyme) that partially or completely alleviates, ameliorates, relieves, suppresses, delays the onset of, reduces the severity of, and / or reduces the incidence of one or more symptoms or characteristics of a particular disease, disorder, and / or condition (e.g., Hunter Syndrome, Sanfilippo Syndrome Type B). Such treatment may be of subjects who do not exhibit signs of the relevant disease, disorder, and / or condition, and / or who exhibit only early signs of the disease, disorder, and / or condition. Alternatively or additionally, such treatment may be of subjects who exhibit one or more established signs of the relevant disease, disorder, and / or condition.

[0069] The present invention provides, inter alia, improved methods and compositions for effective direct delivery of therapeutic agents to the central nervous system (CNS). As described above, the present invention is based on the unexpected discovery that replacement enzymes (e.g., I2S proteins) for lysosomal storage diseases (e.g., Hunter syndrome) can be directly introduced into the cerebrospinal fluid (CSF) of subjects in need of treatment at high concentrations without inducing substantial side effects in the subject. Even more unexpectedly, the inventors have found that the replacement enzymes can be delivered in simple saline or buffer-based formulations without using synthetic CSF. Even more unexpectedly, intrathecal delivery according to the present invention does not result in substantial side effects in the subject, such as severe immune responses. Thus, in some embodiments, intrathecal delivery according to the present invention can be used in the absence of concurrent immunosuppressant therapy (e.g., without induction of immune tolerance by pretreatment or preconditioning).

[0070] In some embodiments, intrathecal delivery according to the present invention allows efficient diffusion through various brain tissues, resulting in effective delivery of replacement enzymes in various target brain tissues in superficial, superficial and / or deep brain regions. In some embodiments, intrathecal delivery according to the present invention results in sufficient amounts of replacement enzymes to enter peripheral circulation. As a result, in some cases, intrathecal delivery according to the present invention results in delivery of replacement enzymes in peripheral tissues such as the liver, heart, spleen and kidney. This finding is unexpected and may be particularly useful for the treatment of lysosomal storage diseases that have both CNS and peripheral components, which typically require regular intrathecal and intravenous administration. It is contemplated that intrathecal delivery according to the present invention may allow for reduced dosage and / or frequency of intravenous injections without compromising therapeutic efficacy in treating peripheral symptoms.

[0071] The present invention provides a variety of unexpected and beneficial features that allow for the efficient and convenient delivery of replacement enzymes to a variety of brain target tissues resulting in effective treatment of lysosomal storage diseases having CNS manifestations.

[0072] Various aspects of the present invention are described in detail in the following sections. The descriptions in the sections are not intended to limit the present invention. Each statement may apply to any aspect of the present invention. In this application, "or" means "and / or" unless otherwise stated. supplemental enzyme Iduronate-2-sulfatase (I2S) protein

[0073] In some embodiments, the inventive methods and compositions provided by the present invention are used to deliver iduronate-2-sulfatase (I2S) protein to the CNS for the treatment of Hunter syndrome. A suitable I2S protein can be any molecule or part of a molecule that can replace naturally occurring iduronate-2-sulfatase (I2S) protein activity or rescue one or more phenotypes or symptoms of I2S deficiency. In some embodiments, a suitable replacement enzyme for the present invention is a polypeptide having an N-terminus and C-terminus and an amino acid sequence substantially similar or identical to the mature human I2S protein.

[0074] Typically, human I2S is produced as a precursor form. The precursor form of human I2S contains a signal peptide (amino acid residues 1-25 of the full-length precursor), a propeptide (amino acid residues 26-33 of the full-length precursor), and a chain (residues 34-550 of the full-length precursor) that can be further processed to a 42 kDa chain (residues 34-455 of the full-length precursor) and a 14 kDa chain (residues 446-550 of the full-length precursor). Typically, this precursor form is also called the full-length precursor or full-length I2S protein, which contains 550 amino acids. The amino acid sequence (SEQ ID NO: 1) of a typical wild-type or naturally occurring mature form of the human I2S protein with the signal peptide removed and the full-length precursor (SEQ ID NO: 2) is shown in Table 1. [Table 1]

[0075] Thus, in some embodiments, a suitable replenishment enzyme for the present invention is the mature human I2S protein (SEQ ID NO:1). In some embodiments, a suitable replenishment enzyme may be a homolog or analog of the mature human I2S protein. For example, a homolog or analog of the mature human I2S protein may be a modified human I2S protein that contains one or more amino acid substitutions, deletions, and / or insertions compared to the wild-type or naturally occurring I2S protein (e.g., SEQ ID NO:1) while retaining substantial I2S protein activity. Thus, in some embodiments, a suitable replenishment enzyme for the present invention is substantially homologous to the mature human I2S protein (SEQ ID NO:1). In some embodiments, a suitable replenishment enzyme for the present invention has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO:1. In some embodiments, the replacement enzyme suitable for the present invention is nearly identical to the mature human I2S protein (SEQ ID NO: 1). In some embodiments, the replacement enzyme suitable for the present invention has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 1. In some embodiments, the replacement enzyme suitable for the present invention contains a fragment or portion of the mature human I2S protein.

[0076] Alternatively, a suitable replacement enzyme for the present invention is a full-length I2S protein. In some embodiments, a suitable replacement enzyme may be a homolog or analog of the full-length human I2S protein. For example, a homolog or analog of the full-length human I2S protein may be a modified full-length human I2S protein that contains one or more amino acid substitutions, deletions, and / or insertions compared to the wild-type or naturally occurring full-length I2S protein (e.g., SEQ ID NO:2) while retaining substantial I2S protein activity. Thus, in some embodiments, a replacement enzyme for the present invention is substantially homologous to the full-length human I2S protein (SEQ ID NO:2). In some embodiments, a suitable replacement enzyme for the present invention has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to SEQ ID NO:2. In some embodiments, the replenishing enzyme suitable for the present invention is nearly identical to SEQ ID NO:2. In some embodiments, the replenishing enzyme suitable for the present invention has an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:2. In some embodiments, the replenishing enzyme suitable for the present invention contains a fragment or portion of the full-length human I2S protein. As used herein, the full-length I2S protein typically contains a signal peptide sequence. Other lysosomal storage disorders and replacement enzymes

[0077] The methods of the invention are directed to any lysosomal storage disease, particularly lysosomal storage diseases with CNS etiology and / or symptoms, such as aspartylglucosaminuria, cholesterol ester storage disease, Wolman disease, cystinosis, Danon disease, Fabry disease, Farber lipogranulomatosis, Farber disease, fucosidosis, galactosialidosis I / II, Gaucher disease I / II / III, globoid cell leukodystrophy, Krabbe disease, glycogen storage disease type II, Pompe disease, GM1-gangliosidosis I / II / III, GM2-gangliosidosis I, Tay-Sachs disease, GM2-gangliosidosis type II, Sandhoff disease, GM2-gangliosidosis, α-mannosidosis I / II, β-mannosidosis, metachromatic leukodystrophy, mucolipidosis I, sialidosis I / II, mucolipidosis II / III, mucopolysaccharidosis type IV, I-cell disease, mucopolypidosis type IIIC, pseudo-Hurler polydystrophy, mucopolysaccharidosis type I, mucopolysaccharidosis type II, Hunter syndrome, mucopolysaccharidosis type IIIA, Sanfilippo syndrome A, B or D, mucopolysaccharidosis type IIIB, mucopolysaccharidosis type IIIC, mucopolysaccharidosis type IIID, mucopolysaccharidosis type IVA, Morquio syndrome, mucopolysaccharidosis type IVB, mucopolysaccharidosis type VI, mucopolysaccharidosis type VII, Sly syndrome, mucopolysaccharidosis type IX, multiple sulfatase deficiency, neuronal ceroid lipofuscinosis, CLN1 Batten disease, CLN2 Batten disease, Niemann-Pick disease types A / B, Niemann-Pick disease type C1, Niemann-Pick disease type C2, pyknotic dysostosis, Schindler disease It is believed that the compounds may be used to treat a variety of conditions, including but not limited to type I / II, Gaucher's disease and sialic acid storage diseases.

[0078] The genetic etiology, clinical manifestations, and molecular biology of lysosomal storage diseases are reviewed in Scriver et al., eds., The Metabolic and Molecular Basis of Inherited Disease, 7.sup.th Ed., Vol. II, McGraw Hill, (1995). Thus, the enzyme deficiencies in the above diseases are known to those skilled in the art, and some of these are illustrated in the following table: Table 2 [Table 2-1] [Table 2-2] [Table 2-3]

[0079] The method of the present invention can be used to deliver various other replacement enzymes.As used herein, the replacement enzyme suitable for the present invention can include any enzyme that can act to replace at least part of the activity of the lysosomal enzyme that is deficient or missing in the lysosomal storage disease to be treated.In some embodiments, the replacement enzyme can reduce the stored material in lysosomes, or rescue or improve one or more lysosomal storage disease symptoms.

[0080] In some embodiments, the suitable replacement enzyme can be any lysosomal enzyme known to be associated with the lysosomal storage disease to be treated. In some embodiments, the suitable replacement enzyme is an enzyme selected from the enzymes listed in Table 2 above.

[0081] In some embodiments, the replacement enzymes suitable for the present invention may have a wild-type or native sequence. In some embodiments, the replacement enzymes suitable for the present invention may have a modified sequence that has substantial homology or identity to the wild-type or native sequence (e.g., has at least 70%, 75%, 80%, 85%, 90%, 95%, 98% sequence identity to the wild-type or native sequence).

[0082] Replacement enzymes suitable for the present invention may be produced by any available means. For example, replacement enzymes may be produced recombinantly by utilizing a host cell system engineered to express a replacement enzyme-encoding nucleic acid. Alternatively or additionally, replacement enzymes may be produced by activating an endogenous gene. Alternatively or additionally, replacement enzymes may be prepared, partially or completely, by chemical synthesis. Alternatively or additionally, replacement enzymes may be purified from natural sources.

[0083] If the enzyme is produced recombinantly, any expression system may be used, such as egg cells, baculovirus, plant cells, yeast or mammalian cells, to name just a few known expression systems.

[0084] In some embodiments, enzymes suitable for the present invention are produced in mammals. Non-limiting examples of mammalian cells that may be used in accordance with the present invention include: BALB / c mouse myeloma line (NSO / l, ECACC number: 85110503); human retinoblastoma cells (PER.C6, CruCell, Leiden, The Netherlands); SV40-transformed monkey kidney CV1 line (COS-7, ATCC CRL 1651); human embryonic kidney lines (293 or 293 cells (subcloned for growth in suspension culture), Graham et al., J. Gen Virol., 36:59,1977); human fibrosarcoma cell lines (e.g., HT1080); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells + / -DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216, 1980); mouse Sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251, 1980); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1 587); human cervical carcinoma cells (HeLa, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat hepatocytes (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human hepatocytes (Hep G2, HB 8065); mouse mammary carcinoma (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals NY Acad. Sci., 383:44-68, 1982); MRC 5 cells; FS4 cells; and a human hepatocellular carcinoma line (Hep G2).

[0085] In some embodiments, the methods of the invention are used to deliver replacement enzymes produced from human cells, hi some embodiments, the methods of the invention are used to deliver replacement enzymes produced from CHO cells.

[0086] In some embodiments, the replacement enzymes delivered using the methods of the present invention contain moieties that bind to receptors on the surface of brain cells to facilitate cellular uptake and / or lysosomal targeting. For example, such receptors can be the cation-independent mannose-6-phosphate receptor (CI-MPR), which binds mannose-6-phosphate (M6P) residues. In addition, CI-MPR also binds other proteins, such as IGF-II. In some embodiments, replacement enzymes suitable for the present invention contain M6P residues on the surface of the protein. In some embodiments, replacement enzymes suitable for the present invention can contain bis-phosphorylated oligosaccharides that have a higher binding affinity to CI-MPR. In some embodiments, suitable enzymes contain up to an average of approximately at least 20% bis-phosphorylated oligosaccharides per enzyme. In other embodiments, suitable enzymes may contain about 10%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% bis-phosphorylated oligosaccharides per enzyme. It should be noted that such bis-phosphorylated oligosaccharides may be naturally present on the enzyme, but the enzyme may be modified to carry such oligosaccharides. For example, a suitable supplementary enzyme may be modified with certain enzymes that can catalyze the transfer of N-acetylglucosamine-L-phosphate from UDP-GlcNAc to the 6' position of α-1,2-linked mannose on a lysosomal enzyme. Methods and compositions for producing and using such enzymes are described, for example, by Canfield et al. in U.S. Pat. Nos. 6,537,785 and 6,534,300, each of which is incorporated herein by reference.

[0087] In some embodiments, replacement enzymes for use in the present invention may be conjugated or fused to a lysosomal targeting moiety capable of binding to a receptor on the surface of brain cells. Suitable lysosomal targeting moieties may be IGF-I, IGF-II, RAP, p97, as well as variants, homologues or fragments thereof (e.g., peptides having a sequence at least 70%, 75%, 80%, 85%, 90% or 95% identical to the wild-type mature human IGF-I, IGF-II, RAP, p97 peptide sequence).

[0088] In some embodiments, replacement enzymes suitable for the present invention have not been modified to enhance delivery or transport of such agents across the BBB and into the CNS.

[0089] In some embodiments, the therapeutic protein comprises a targeting moiety (e.g., a lysosomal targeting sequence) and / or a membrane penetrating peptide. In some embodiments, the targeting sequence and / or the membrane penetrating peptide are endogenous portions of the therapeutic moiety (e.g., via chemical conjugation, via a fusion protein). In some embodiments, the targeting sequence contains a mannose-6-phosphate moiety. In some embodiments, the targeting sequence contains an IGF-1 moiety. In some embodiments, the targeting sequence contains an IGF-II moiety. formulation

[0090] In some embodiments, the desired enzyme is delivered in a stable formulation for intrathecal delivery. Certain embodiments of the present invention are based, at least in part, on the discovery that various formulations disclosed herein facilitate effective delivery and distribution of one or more therapeutic agents (e.g., enzymes) to targeted tissues, cells and / or organelles of the CNS. In particular, the formulations described herein can solubilize high concentrations of therapeutic agents (e.g., proteins or enzymes) and are suitable for delivering such therapeutic agents to the CNS of a subject for the treatment of diseases that have a CNS component and / or etiology. The compositions described herein are further characterized by improved stability and improved tolerability when administered to the CNS of a subject in need thereof (e.g., intrathecally).

[0091] Prior to the present invention, traditional unbuffered isotonic saline and Elliot's B solution (artificial CSF) were typically used for intrathecal delivery. A comparison depicting the composition of CSF to Elliot's B solution is included in Table 3 below. As shown in Table 3, the concentrations of Elliot's B solution closely resemble those of CSF. However, Elliot's B solution contains an extremely low buffer concentration and therefore may not provide the appropriate buffering capacity required to stabilize therapeutic agents (e.g., proteins), especially over long periods of time (e.g., during storage conditions). Furthermore, Elliot's B solution contains certain salts that may be incompatible with formulations intended to deliver some therapeutic agents, especially proteins or enzymes. For example, calcium salts present in Elliot's B solution may mediate protein precipitation, thereby reducing the stability of the formulation. [Table 3]

[0092] Thus, in some embodiments, formulations suitable for intrathecal delivery according to the present invention are not synthetic or artificial CSFs.

[0093] In some embodiments, formulations for intrathecal delivery are formulated such that they can stabilize or slow or prevent the degradation of one or more therapeutic agents (e.g., recombinant proteins) with which they are formulated. As used herein, the term "stable" refers to the ability of a therapeutic agent (e.g., recombinant enzyme) to retain its therapeutic efficacy (e.g., all or a majority of its intended biological activity and / or physicochemical integrity) over an extended period of time. The stability of a therapeutic agent, as well as the ability of a pharmaceutical composition to retain such stability of a therapeutic agent, can be assessed over an extended period of time (e.g., preferably at least 1, 3, 6, 12, 18, 24, 30, 36 months or more). In the context of a formulation, a stable formulation is one in which the therapeutic agent therein essentially retains its physical and / or chemical integrity and biological activity during storage and processing (e.g., freeze / thaw, mechanical mixing and lyophilization). With respect to protein stability, it can be measured by the formation of high molecular weight (HMW) aggregates, loss of enzyme activity, generation of peptide fragments, and shifts in charge profile.

[0094] The stability of a therapeutic agent is of particular importance. The stability of a therapeutic agent can be further assessed with respect to the biological activity or physicochemical integrity of the therapeutic agent over an extended period of time. For example, the stability at a given time point can be compared to the stability at an earlier time point (e.g., day 0 of formulation) or to the unformulated therapeutic agent. The results of this comparison are expressed as a percentage. Preferably, the pharmaceutical compositions of the invention retain at least 100%, at least 99%, at least 98%, at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% of the biological activity or physicochemical integrity of the therapeutic agent over an extended period of time (e.g., measured at room temperature or under accelerated storage conditions for at least 6-12 months).

[0095] In some embodiments, the therapeutic agent (e.g., a desired enzyme) is soluble in the formulation of the present invention. The term "soluble" refers to the ability of such a therapeutic agent to form a homogenous solution. Preferably, the solubility of the therapeutic agent in the solution in which it is administered and in which it is transported to the target site of action (e.g., cells and tissues of the brain) is sufficient to allow delivery of a therapeutically effective amount of the therapeutic agent to the target site of action. Several factors can affect the solubility of the therapeutic agent. For example, relevant factors that can affect protein solubility include ionic strength, amino acid sequence, and the presence of other co-solubilizing agents or salts (e.g., calcium salts). In some embodiments, the pharmaceutical composition is formulated such that calcium salts are removed from such compositions.

[0096] Suitable formulations, whether in aqueous, pre-lyophilized, lyophilized or reconstituted form, may contain the therapeutic agent of interest at various concentrations. In some embodiments, the formulations contain the protein or therapeutic agent of interest at a concentration ranging from about 0.1 mg / ml to 100 mg / ml (e.g., from about 0.1 mg / ml to 80 mg / ml, from about 0.1 mg / ml to 60 mg / ml, from about 0.1 mg / ml to 50 mg / ml, from about 0.1 mg / ml to 40 mg / ml, from about 0.1 mg / ml to 30 mg / ml, from about 0.1 mg / ml to 25 mg / ml, from about 0.1 mg / ml to 20 mg / ml, from about 0.1 mg / ml to 60 mg / ml, from about 0.1 mg / ml to 50 mg / ml, from about 0.1 mg / ml to 50 mg / ml, from about 0.1 mg / ml to 60 mg / ml, from about 0.1 mg / ml to 70 mg / ml, from about 0.1 mg / ml to 80 mg / ml, from about 0.1 mg / ml to 90 mg / ml, from about 0.1 mg / ml to 100 mg / ml, from about 0.1 mg / ml to 150 mg / ml, from about 0.1 mg / ml to 20 mg / ml, from about 0.1 mg / ml to 30 mg / ml, from about 0.1 mg / ml to 25 mg / ml, from about 0.1 mg / ml to 20 mg / ml, from about 0.1 mg / ml to 60 mg / ml, from about 0.1 mg / ml to 50 mg / ml, from about 0.1 mg / ml to 100 mg / ml, from about 0.1 mg / ml to 150 mg / ml, from about 0.1 mg / ml to 200 mg / ml, from about The compound may contain the compound at a concentration of about 0.1 mg / ml to 40 mg / ml, about 0.1 mg / ml to 30 mg / ml, about 0.1 mg / ml to 25 mg / ml, about 0.1 mg / ml to 20 mg / ml, about 0.1 mg / ml to 15 mg / ml, about 0.1 mg / ml to 10 mg / ml, about 0.1 mg / ml to 5 mg / ml, about 1 mg / ml to 10 mg / ml, about 1 mg / ml to 20 mg / ml, about 1 mg / ml to 40 mg / ml, about 5 mg / ml to 100 mg / ml, about 5 mg / ml to 50 mg / ml, or about 5 mg / ml to 25 mg / ml. In some embodiments, formulations according to the invention may contain a therapeutic agent at a concentration of about 1 mg / ml, 5 mg / ml, 10 mg / ml, 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml, 40 mg / ml, 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, 90 mg / ml, or 100 mg / ml.

[0097] The formulations of the present invention are characterized by their tolerability, either as aqueous solution or as reconstituted lyophilized solution.As used herein, the terms "tolerable" and "tolerability" refer to the ability of the pharmaceutical composition of the present invention to not induce adverse reactions in the subject to which such composition is administered, or to not induce serious adverse reactions in the subject to which such composition is administered.In some embodiments, the pharmaceutical composition of the present invention is well tolerated by the subject to which such composition is administered.

[0098] Many therapeutic agents, particularly the proteins and enzymes of the invention, require controlled pH and specific excipients to maintain their solubility and stability in the pharmaceutical compositions of the invention. Table 4 below identifies exemplary exemplary aspects of protein formulations that are considered important for maintaining the solubility and stability of the protein therapeutic agents of the invention. [Table 4] buffer solution

[0099] The pH of the formulation is an additional factor that can alter the solubility of a therapeutic agent (e.g., an enzyme or protein) in an aqueous formulation or for a pre-lyophilized formulation. Thus, it is preferred that the formulations of the invention include one or more buffers. In some embodiments, the aqueous formulation includes an amount of buffer sufficient to maintain the optimal pH of the composition between about 4.0-8.0 (e.g., about 4.0, 4.5, 5.0, 5.5, 6.0, 6.2, 6.4, 6.5, 6.6, 6.8, 7.0, 7.5, or 8.0). In some embodiments, the pH of the formulation is between about 5.0-7.5, between about 5.5-7.0, between about 6.0-7.0, between about 5.5-6.0, between about 5.5-6.5, between about 5.0-6.0, between about 5.0-6.5, and between about 6.0-7.5. Suitable buffers include, for example, acetate, citrate, histidine, phosphate, succinate, tris(hydroxymethyl)aminomethane ("Tris") and other organic acids. The buffer concentration and pH range of the pharmaceutical composition of the present invention are factors in controlling or adjusting the tolerability of the formulation. In some embodiments, the buffer is present at a concentration ranging from about 1 mM to about 150 mM, or from about 10 mM to about 50 mM, or from about 15 mM to about 50 mM, or from about 20 mM to about 50 mM, or from about 25 mM to about 50 mM. In some embodiments, the suitable buffer is present at a concentration of about 1 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 75 mM, 100 mM, 125 mM or 150 mM. Osmolarity

[0100] In some embodiments, the formulation, whether in aqueous, pre-lyophilized, lyophilized or reconstituted form, contains an isotonicity agent to keep the formulation isotonic. In general, "isotonic" means that the formulation has essentially the same osmotic pressure as human blood. An isotonic formulation will generally have an osmotic pressure of about 240 mOsm / kg to about 350 mOsm / kg. Isotonicity can be measured, for example, using a vapor pressure or freezing point osmometer. Exemplary isotonicity agents include, but are not limited to, glycine, sorbitol, mannitol, sodium chloride and arginine. In some embodiments, a suitable isotonicity agent may be present in the aqueous and / or pre-lyophilized formulation at a concentration of about 0.01-5% by weight (e.g., 0.05, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 0.75, 1.0, 1.25, 1.5, 2.0, 2.5, 3.0, 4.0, or 5.0% by weight). In some embodiments, the formulation for lyophilization contains an isotonicity agent to keep the pre-lyophilized or reconstituted formulation isotonic.

[0101] Generally, isotonic solutions are suitable for parenterally administered drugs, but the use of isotonic agents may alter the solubility of some therapeutic drugs, especially some proteins and / or enzymes. Slightly hypertonic solutions (e.g., up to 175 mM sodium chloride in 5 mM sodium phosphate at pH 7.0) and sugar-containing solutions (e.g., up to 2% sucrose in 5 mM sodium phosphate at pH 7.0) have proven to be well tolerated. The most commonly approved CNS administration formulation is saline (about 150 mM NaCl in water). Stabilizers

[0102] In some embodiments, the formulation may contain a stabilizer, or lyoprotectant, to protect the protein. Typically, suitable stabilizers are sugars, non-reducing sugars, and / or amino acids. Exemplary sugars include, but are not limited to, dextran, lactose, mannitol, mannose, sorbitol, raffinose, sucrose, and trehalose. Exemplary amino acids include, but are not limited to, arginine, glycine, and methionine. Additional stabilizers can include sodium chloride, hydroxyethyl starch, and polyvinylpyrrolidone. The amount of stabilizer in the lyophilized formulation is approximately such that the formulation is isotonic. However, hypertonic reconstituted formulations may also be suitable. Furthermore, the amount of stabilizer should not be too low, such that an unacceptable amount of degradation / aggregation of the therapeutic agent occurs. Exemplary stabilizer concentrations in the formulation may range from about 1 mM to about 400 mM (e.g., about 30 mM to about 300 mM, and about 50 mM to about 100 mM), or from 0.1% to 15% by weight (e.g., 1% to 10% by weight, 5% to 15% by weight, 5% to 10% by weight). In some embodiments, the ratio of mass of stabilizer and therapeutic agent is about 1:1. In other embodiments, the ratio of mass of stabilizer and therapeutic agent can be about 0.1:1, 0.2:1, 0.25:1, 0.4:1, 0.5:1, 1:1, 2:1, 2.6:1, 3:1, 4:1, 5:1, 10:1, or 20:1. In some embodiments, stabilizers suitable for lyophilization are also lyoprotectants.

[0103] In some embodiments, liquid formulations suitable for the present invention contain amorphous material. In some embodiments, liquid formulations suitable for the present invention contain a substantial amount of amorphous material (e.g., sucrose-based formulations). In some embodiments, liquid formulations suitable for the present invention contain partially crystalline / partially amorphous material. Bulking Agent

[0104] In some embodiments, the formulation suitable for liquid lyophilization may further include one or more bulking agents. A "bulking agent" adds mass to the lyophilization mixture and is involved in the physical structure of the lyophilized cake. For example, a bulking agent may improve the appearance of the lyophilized cake (e.g., an essentially uniform lyophilized cake). Suitable bulking agents include, but are not limited to, sodium chloride, lactose, mannitol, glycine, sucrose, trehalose, and hydroxyethyl starch. Exemplary concentrations of bulking agents are about 1% to about 10% (e.g., 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, and 10.0%). Surfactants

[0105] In some embodiments, it may be desirable to add a surfactant to the formulation. Examples of surfactants include polysorbates (e.g., polysorbate 20 or 80); poloxamers (e.g., poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g., lauroamidopropyl); myristalnidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl- or disodium methyl isofeyl-taurate; and the MONAQUAT™ series (Mona Industries, Inc., Paterson, NJ), polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g., Pluronic, PF68, etc.). Typically, the amount of surfactant added is such that it reduces protein aggregation and minimizes particulate formation or foaming. For example, the surfactant may be present in the formulation at a concentration of about 0.001-0.5% (e.g., about 0.005-0.05% or 0.005-0.01%). In particular, the surfactant may be present in the formulation at a concentration of about 0.005%, 0.01%, 0.02%, 0.1%, 0.2%, 0.3%, 0.4% or 0.5%, etc.

[0106] Other pharma- ceutically acceptable carriers, excipients, or stabilizers, such as those described in Remington's Pharmaceutically Sciences, 16th ed., edited by Osol, A. (1980), may be included in the formulation (and / or lyophilized formulation and / or reconstituted formulation), provided that they do not adversely affect the desired properties of the formulation. Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations used, and include, but are not limited to, additional buffering agents; preservatives; cosolvents; antioxidants, including ascorbic acid and methionine; chelating agents, such as EDTA; metal complexes (e.g., Zn-protein complexes); biodegradable polymers, such as polyesters; and / or salt-forming counterions, such as sodium.

[0107] Formulations according to the present invention in either aqueous, pre-lyophilized, lyophilized or reconstituted form can be assessed based on quality analysis, reconstitution time (if lyophilized), reconstitution quality (if lyophilized), high molecular weight, moisture and glass transition temperature. Typically, protein quality and product analysis includes product degradation rate analysis using methods including, for example, size exclusion HPLC (SE-HPLC), cation exchange-HPLC (CEX-HPLC), X-ray diffraction (XRD), modulated differential scanning calorimetry (mDSC), reverse phase HPLC (RP-HPLC), multi-angle light scattering (MALS), fluorescence, ultraviolet absorption, nephelometry, capillary electrophoresis (CE), SDS-PAGE and combinations thereof, but not limited thereto. In some embodiments, evaluation of products according to the present invention includes evaluating appearance (either liquid or cake appearance).

[0108] Generally, the formulations (lyophilized or aqueous) can be stored at room temperature for long periods of time. Storage temperatures can typically range from 0° C. to 45° C. (e.g., 4° C., 20° C., 25° C., 45° C., etc.). The formulations can be stored for months to years. Storage times are typically 24 months, 12 months, 6 months, 4.5 months, 3 months, 2 months, or 1 month. The formulations can be stored directly in the container used for administration, eliminating a transfer step.

[0109] The product can be stored directly in the lyophilization container (if lyophilized), which can also serve as the reconstitution container, eliminating the transfer step. Alternatively, the lyophilized material formulation can be measured in smaller increments for storage. Storage should generally avoid environments that cause protein degradation, such as, but not limited to, exposure to sunlight, ultraviolet light and other forms of electromagnetic radiation, excessive heat or cold, rapid heat shock, and mechanical shock. Freeze drying

[0110] The inventive method according to the present invention can be used to lyophilize any material, particularly therapeutic agents. Typically, the pre-lyophilized formulation further includes an appropriate selection of other components, such as excipients or stabilizers, buffers, bulking agents, and surfactants, to inhibit degradation of the compound of interest (e.g., protein aggregation, deamidation, and / or oxidation) during lyophilization and storage. Formulations for lyophilization can include one or more additional components, including lyoprotectants or stabilizers, buffers, bulking agents, isotonicity agents, and surfactants.

[0111] After the substance of interest and any additional ingredients are mixed together, the formulation is freeze-dried. Freeze-drying generally involves three main stages: freezing, primary drying, and secondary drying. Freezing is necessary to convert water to ice or some amorphous formulation ingredients to crystalline form. Primary drying is a process step where ice is removed from the frozen product by direct sublimation at low pressure and temperature. Secondary drying is a process step where bound water is removed from the product matrix using diffusion of the remaining water to the evaporative surface. The product temperature during secondary drying is usually higher than during primary drying. Tang X. et al. (2004) "Design of freeze-drying processes" See, for example, "Lyophilization of solid protein pharmaceuticals: Practical advice," Pharm. Res., 21:191-200; Nail SL et al. (2002) "Fundamentals of freeze-drying," in Development and manufacture of protein pharmaceuticals., edited by Nail SL, New York: Kluwer Academic / Plenum Publishers, pp. 281-353; Wang et al. (2000) "Lyophilization and development of solid protein pharmaceuticals," Int. J. Pharm. 203:1-60; Williams NA et al. (1984) "The Lyophilization of pharmaceuticals; A literature review," J. Parenteral Sci. Technol., 38:48-59. Generally, any freeze-drying process may be used in connection with the present invention.

[0112] In some embodiments, an annealing step may be introduced during the initial freezing of the product. The annealing step may reduce the overall cycle time. Without wishing to be bound by any theory, it is believed that the annealing step helps to promote excipient crystallization and the formation of larger ice crystals due to the recrystallization of small crystals formed during supercooling, which in turn improves reconstitution. Typically, the annealing step involves an interval or oscillation in temperature during freezing. For example, the freezing temperature may be -40°C, and the annealing step would increase the temperature, for example to -10°C, and maintain this temperature for a set period of time. The annealing step time may range from 0.5 hours to 8 hours (e.g., 0.5, 1.0, 1.5, 2.0, 2.5, 3, 4, 6, and 8 hours). The annealing temperature may be between the freezing temperature and 0°C.

[0113] Lyophilization may be carried out in a container such as a tube, bag, bottle, tray, vial (e.g., glass vial), syringe or other suitable container. The container may be disposable. Lyophilization may also be carried out on a large or small scale. In some instances, it is desirable to lyophilize the protein formulation in the container in which the protein reconstitution is to be carried out to avoid a transfer step. The container in this instance may be, for example, a 3, 4, 5, 10, 20, 50 or 100 cc vial.

[0114] A variety of freeze dryers can be used for this purpose, such as Hull pilot scale dryer (SP Industries, USA), Genesis (SP Industries) laboratory freeze dryer, or any freeze dryer capable of controlling predetermined freeze drying process parameters. Freeze drying is accomplished by freezing the formulation followed by sublimation of ice from the frozen contents at a suitable temperature for primary drying. The initial freezing typically brings the formulation to a temperature of about -20°C or below (e.g., -50°C, -45°C, -40°C, -35°C, -30°C, -25°C, etc.) within about 4 hours (e.g., within about 3 hours, within about 2.5 hours, within about 2 hours). Under these conditions, the product temperature is typically below the eutectic or collapse temperature of the formulation. Typically, the storage temperature for primary drying will be in the range of about -30°C to 25°C (provided that the product remains below its melting point during primary drying), with a suitable pressure typically in the range of 20-250 mTorr. The formulation, the dimensions and type of container (e.g., glass vial) holding the sample, and the volume of liquid will primarily dictate the time required for drying, which may range from a few hours to a few days. The secondary drying stage is carried out at about 0-60°C, depending primarily on the type and dimensions of the container and the type of therapeutic protein. Again, the volume of liquid will primarily dictate the time required for drying, which may range from a few hours to a few days.

[0115] As a general rule, lyophilization will result in lyophilized formulations whose moisture content is less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, and less than about 0.5%. Reconstruction

[0116] The pharmaceutical composition of the present invention is generally in aqueous form when administered to a subject, but in some embodiments, the pharmaceutical composition of the present invention is lyophilized. Such compositions must be reconstituted by adding one or more diluents to them before being administered to a subject. At a desired stage, typically at an appropriate time before being administered to a patient, the lyophilized formulation can be reconstituted with a diluent so that the protein concentration in the reconstituted formulation is the desired one.

[0117] Various diluents may be used according to the present invention.In some embodiments, the suitable diluent for formulation is water.The water used as diluent can be treated in various ways, including reverse osmosis, distillation, deionization, filtration (e.g., activated carbon, microfiltration, nanofiltration) and combinations of these treatment methods.Generally, water should be suitable for injection, including but not limited to sterile water or bacteriostatic water for injection.

[0118] Additional exemplary diluents include pH buffered solutions (e.g., phosphate-buffered saline), sterile saline, Elliot's solution, Ringer's solution, or dextrose solution. Suitable diluents contain preservatives, if necessary. Exemplary preservatives include aromatic alcohols, such as benzyl or phenol alcohol. The amount of preservative used is determined by evaluating different preservative concentrations for possible combinations in protein and preservative efficacy tests. For example, if the preservative is an aromatic alcohol (such as benzyl alcohol), it can be present in an amount of about 0.1-2.0%, about 0.5-1.5%, or about 1.0-1.2%.

[0119] Diluents suitable for the present invention may contain a variety of additives including, but not limited to, pH buffers (e.g., Tris, histidine), salts (e.g., sodium chloride) and other additives including those mentioned above (e.g., stabilizers, isotonicity agents) (e.g., sucrose).

[0120] According to the present invention, lyophilized material (e.g., protein) can be reconstituted to a concentration of at least 25 mg / ml (e.g., at least 50 mg / ml, at least 75 mg / ml, at least 100 mg / ml) and any range of concentrations therebetween. In some embodiments, the lyophilized material (e.g., protein) may be reconstituted to a concentration in the range of about 1 mg / ml to 100 mg / ml (e.g., about 1 mg / ml to 50 mg / ml, about 1 mg / ml to 100 mg / ml, about 1 mg / ml to about 5 mg / ml, about 1 mg / ml to about 10 mg / ml, about 1 mg / ml to about 25 mg / ml, about 1 mg / ml to about 75 mg / ml, about 10 mg / ml to about 30 mg / ml, about 10 mg / ml to about 50 mg / ml, about 10 mg / ml to about 75 mg / ml, about 10 mg / ml to about 100 mg / ml, about 25 mg / ml to about 50 mg / ml, about 25 mg / ml to about 75 mg / ml, about 25 mg / ml to about 100 mg / ml, about 50 mg / ml to about 75 mg / ml, about 50 mg / ml to about 100 mg / ml). In some embodiments, the protein concentration in the reconstituted formulation may be higher than the concentration in the pre-lyophilized formulation. High protein concentrations in the reconstituted formulation are believed to be particularly useful when subcutaneous or intramuscular delivery of the reconstituted formulation is intended. In some embodiments, the protein concentration in the reconstituted formulation may be about 2-50 times (e.g., about 2-10 times, about 2-10 times, or about 2-5 times) that of the pre-lyophilized formulation. In some embodiments, the protein concentration in the reconstituted formulation may be at least about 2 times (e.g., at least about 3, 4, 5, 10, 20, 40 times) that of the pre-lyophilized formulation.

[0121] Reconstitution according to the present invention may be carried out in any container. Exemplary containers suitable for the present invention include, but are not limited to, tubes, vials, syringes (e.g., one or two chambers), bags, bottles, and trays. Suitable containers may be made of any material, such as glass, plastic, metal, etc. The container may be disposable or reusable. Reconstitution may also be carried out on a large or small scale.

[0122] In some instances, it is desirable to lyophilize the protein formulation in the container in which the protein reconstitution is to be carried out, to avoid the transfer step. The container in this instance may be a 3, 4, 5, 10, 20, 50 or 100 cc vial. In some embodiments, the container suitable for lyophilization and reconstitution is a dual-chamber syringe (e.g., Lyo-Ject® (Vetter) syringe). For example, the dual-chamber syringe may contain both the lyophilized material and the diluent in each of the separate chambers separated by a stopper (see Example 5). To reconstitute, a plunger is attached to the stopper on the diluent side, and can be pushed to allow the diluent to contact the lyophilized material, moving the diluent into the product chamber, where reconstitution can be carried out, as described herein (see Example 5).

[0123] The pharmaceutical compositions, formulations, and related methods of the present invention are useful for delivering various therapeutic agents to the CNS of a subject (e.g., intrathecal, intraventricular, intracerebrospinal) and for treating related diseases. The pharmaceutical compositions of the present invention are particularly useful for delivering proteins and enzymes to subjects suffering from lysosomal storage diseases (e.g., enzyme replacement therapy). Lysosomal storage diseases represent a group of relatively rare inherited metabolic disorders resulting from defective lysosomal function. Lysosomal diseases are characterized by the accumulation of undigested macromolecules in lysosomes, leading to an increase in the size and number of such lysosomes, ultimately resulting in cellular dysfunction and clinical abnormalities. CNS delivery

[0124] The various stable formulations described herein are generally considered suitable for CNS delivery of therapeutic agents.The stable formulations according to the present invention can be used for CNS delivery through various techniques and routes, including but not limited to intraparenchymal administration, intracerebral administration, intracerebroventricular (ICV) administration, intrathecal (e.g. IT-lumbar, IT-cisterna) administration, and through any other techniques and routes for direct or indirect injection into the CNS and / or CSF. Intrathecal delivery

[0125] In some embodiments, the replacement enzyme is delivered to the CNS in a formulation described herein. In some embodiments, the replacement enzyme is delivered to the CNS by administration into the cerebrospinal fluid (CSF) of a subject in need of treatment. In some embodiments, intrathecal administration is used to deliver the desired replacement enzyme (e.g., I2S protein) into the CSF. As used herein, intrathecal administration (also referred to as intrathecal injection) refers to injection into the spinal canal (the intrathecal space surrounding the spinal cord). A variety of techniques may be used, including, but not limited to, lateral ventricular injection via burr hole or cisternal puncture or lumbar puncture, etc. Exemplary methods are described in Lazorthes et al., Advances in Drug Delivery Systems and Applications in Neurosurgery, pp. 143-192, and Omaya et al., Cancer Drug Delivery, 1:169-179, the contents of which are incorporated herein by reference.

[0126] According to the present invention, the enzyme may be injected in any area around the spinal cord. In some embodiments, the enzyme is injected into the lumbar or cisterna magna, or intraventricularly into the ventricular space. As used herein, the term "lumbar" or "lumbar region" refers to the region between the third and fourth lumbar vertebrae (low back), and more generally, the L2-S1 region of the spine. Typically, intrathecal injection via the lumbar or lumbar region is also referred to as "lumbar IT delivery" or "lumbar IT administration". The term "cisterna magna" refers to the space around and below the cerebellum via the opening between the skull and the top part of the spine. Typically, intrathecal injection via the cisterna magna is also referred to as "cisterna magna delivery". The term "ventricle" refers to the space in the brain that is continuous with the central canal of the spinal cord. Typically, injection via the ventricular space is referred to as intracerebroventricular (ICV) delivery.

[0127] In some embodiments, "intral thecal administration" or "intral thecal delivery" according to the present invention refers to lumbar IT administration or delivery, for example, delivered between the third and fourth lumbar vertebrae (low back), or more generally delivered to the L2-S1 region of the spine. It is believed that lumbar IT administration or delivery is distinct from cisternal delivery in that, among other things, cisternal delivery does not typically deliver well to the distal spinal canal, while lumbar IT administration or delivery according to our invention results in better and more effective delivery to the distal spinal canal. Device for intrathecal delivery

[0128] Various devices can be used for intrathecal delivery according to the present invention. In some embodiments, the device for intrathecal administration contains a fluid access port (e.g., injection port); a first outlet in fluid communication with the fluid access port, and a second outlet designed for insertion into the spinal cord; and a fixation mechanism for fixing the insertion of the hollow body in the spinal cord. As a non-limiting example shown in FIG. 62, a suitable fixation mechanism contains one or more knobs that rest on the surface of the hollow body, and an adjustable suture ring that covers the one or more knobs and prevents the hollow body from slipping out of the spinal cord. In various embodiments, the fluid access port includes a reservoir. In some embodiments, the fluid access port includes a mechanical pump (e.g., an infusion pump). In some embodiments, an implanted catheter is connected to a reservoir (e.g., for bolus delivery) or an infusion pump. The fluid access port can be implanted or external.

[0129] In some embodiments, intrathecal administration may be performed by lumbar puncture (i.e., slow bolus administration) or via a port-catheter delivery system (i.e., infusion or bolus administration). In some embodiments, the catheter is inserted between the lumbar lamina and the tip is loaded into the thecal space at the desired level (typically L3-L4) (Figure 63).

[0130] Compared to intravenous administration, single dose administration volumes suitable for intrathecal administration are typically small. Typically, intrathecal delivery according to the present invention maintains equilibrium of the composition of the CSF, as well as the intracranial pressure of the subject. In some embodiments, intrathecal delivery is performed in the absence of a corresponding removal of CSF from the subject. In some embodiments, a suitable single dose administration volume may be, for example, less than about 10 ml, 8 ml, 6 ml, 5 ml, 4 ml, 3 ml, 2 ml, 1.5 ml, 1 ml, or 0.5 ml. In some embodiments, a suitable single dose administration volume may be about 0.5-5 ml, 0.5-4 ml, 0.5-3 ml, 0.5-2 ml, 0.5-1 ml, 1-3 ml, 1-5 ml, 1.5-3 ml, 1-4 ml, or 0.5-1.5 ml. In some embodiments, intrathecal delivery according to the present invention first involves removing a desired amount of CSF. In some embodiments, less than about 10 ml (e.g., less than about 9 ml, 8 ml, 7 ml, 6 ml, 5 ml, 4 ml, 3 ml, 2 ml, 1 ml) of CSF is first removed and then IT administered. In these cases, suitable single dose administration volumes are, for example, greater than about 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 15 ml, or 20 ml.

[0131] A variety of other devices can be used to carry out intrathecal administration of therapeutic compositions. For example, a formulation containing the desired enzyme can be administered using an Ommaya reservoir, which is commonly used to intrathecally administer drugs for meningeal carcinomatosis (Lancet 2: 983-84, 1963). More specifically, in this method, a ventricular tube is inserted through a hole formed in the anterior horn and connected to an Ommaya reservoir placed under the scalp, which is punctured subcutaneously to deliver intrathecally the specific enzyme to be replenished, which is infused into the reservoir. Other devices for intrathecal administration of therapeutic compositions or formulations to individuals are described in U.S. Pat. No. 6,217,552, the disclosure of which is incorporated herein by reference. Alternatively, the drug can be administered intrathecally, for example, by a single injection or continuous infusion. It should be understood that the dosing treatment can be in the form of a single dose or multiple doses.

[0132] For injection, the preparation of the present invention can be formulated in liquid solution.Furthermore, the enzyme can be formulated in solid form and redissolved or suspended immediately before use.Lyophilized forms are also included.Injection can be, for example, in the form of bolus injection or continuous infusion (e.g., using an infusion pump) of the enzyme.

[0133] In one embodiment of the present invention, the enzyme is administered by lateral ventricular injection into the subject's brain.Injection can be, for example, through a burr hole made in the subject's skull.In another embodiment, the enzyme and / or other pharmaceutical formulation is administered through a shunt that is surgically inserted into the subject's ventricle.For example, injection can be made into the larger lateral ventricle.In some embodiments, injection can also be made into the smaller third and fourth ventricles.

[0134] In yet another embodiment, the pharmaceutical compositions used in the present invention are administered by injection into the cisterna magna or lumbar region of the subject.

[0135] In another embodiment of the methods of the invention, the pharma- ceutical acceptable formulation provides sustained delivery, e.g., "slow release," of the enzyme or other pharmaceutical composition used in the invention to the subject for at least 1, 2, 3, 4 or more weeks after the pharma- ceutical acceptable formulation is administered to the subject.

[0136] As used herein, the term "sustained delivery" refers to the continuous delivery of the pharmaceutical formulation of the present invention in vivo for an extended period of time, preferably at least several days, a week or several weeks, after administration. The sustained delivery of the composition can be demonstrated, for example, by a continuous therapeutic effect of the enzyme over an extended period of time (e.g., the sustained delivery of the enzyme can be demonstrated by a continuous reduction in the amount of storage granules in the subject). Alternatively, the sustained delivery of the enzyme can be demonstrated by detecting the presence of the enzyme in vivo over an extended period of time. Delivery to target tissue

[0137] As mentioned above, one of the surprising and important features of the present invention is that the therapeutic agent, particularly the replacement enzyme, administered using the method of the present invention, as well as the composition of the present invention, can effectively and widely diffuse across the brain surface and penetrate into various layers or regions of the brain, such as deep brain regions.In addition, the method of the present invention and the composition of the present invention effectively deliver the therapeutic agent (e.g., I2S enzyme) to the tissues, neurons or cells of the spinal cord, including the lumbar region, which are difficult to target with existing CNS delivery methods, such as ICV injection.In addition, the method and composition of the present invention deliver sufficient amounts of the therapeutic agent (e.g., I2S enzyme) to the bloodstream and various peripheral organs and tissues.

[0138] Thus, in some embodiments, the therapeutic protein (e.g., I2S enzyme) is delivered to the central nervous system of a subject. In some embodiments, the therapeutic protein (e.g., I2S enzyme) is delivered to one or more of the target tissues in the brain, spinal cord, and / or peripheral period. As used herein, the term "target tissue" refers to any tissue affected by the lysosomal storage disease to be treated or any tissue in which the defective lysosomal enzyme is normally expressed. In some embodiments, the target tissue includes tissues in which the enzyme substrate, e.g., stored in the cellular lysosomes of the tissue, is present in detectable or abnormally high amounts in patients suffering from or susceptible to a lysosomal storage disease. In some embodiments, the target tissue includes tissues that exhibit disease-related pathology, symptoms, or characteristics. In some embodiments, the target tissue includes tissues in which the defective lysosomal enzyme is normally expressed at high levels. As used herein, the target tissue may be a brain target tissue, a spinal cord target tissue, and / or a peripheral target tissue. Examples of target tissues are described in detail below. Brain target tissue

[0139] Generally, the brain can be divided into different regions, layers and tissues. For example, meningeal tissue is a membrane system that encases the central nervous system, including the brain. Meninges contain three layers, such as dura mater, arachnoid mater and pia mater. Generally, the main function of meninges and cerebrospinal fluid is to protect the cranial nervous system. In some embodiments, therapeutic protein according to the present invention is delivered to one or more layers of meninges.

[0140] The brain has three main subdivisions, including the cerebrum, cerebellum, and brain stem. The cerebral hemispheres lie above most other brain structures and are covered by a layer of cortex. Below the cerebrum lies the brain stem, which resembles a stem onto which the cerebrum is attached. At the rear of the brain, below the cerebrum and behind the brain stem, is the cerebellum.

[0141] Located near the midline of the brain and above the midbrain, the diencephalon contains the thalamus, posterior thalamus, hypothalamus, epithalamus, ventral thalamus and ventral tectum. The mesencephalon, also called the midbrain, contains the optic tectum, tectum, ventricular mesocoelia, as well as the cerebral peduncle, red nucleus and third cranial nerve nuclei. The midbrain is associated with vision, hearing, motor control, sleep / wakefulness, vigilance and temperature regulation.

[0142] Regions of tissue in the central nervous system, including the brain, can be characterized based on the depth of the tissue. CNS (e.g., brain) tissue can be characterized as superficial or superficial tissue, intermediate and / or deep tissue.

[0143] According to the present invention, a therapeutic protein (e.g., replacement enzyme) can be delivered to any suitable brain target tissue(s) associated with the particular disease to be treated in a subject. In some embodiments, a therapeutic protein (e.g., replacement enzyme) according to the present invention is delivered to superficial and superficial brain target tissues. In some embodiments, a therapeutic protein according to the present invention is delivered to mid-deep brain target tissues. In some embodiments, a therapeutic protein according to the present invention is delivered to deep brain target tissues. In some embodiments, a therapeutic protein according to the present invention is delivered to a combination of superficial or superficial brain target tissues, mid-deep brain target tissues and / or deep brain target tissues. In some embodiments, a therapeutic protein according to the present invention is delivered to deep brain tissues at least 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm below (or inside) the outer surface of the brain.

[0144] In some embodiments, the therapeutic agent (e.g., enzyme) is delivered to one or more surface or superficial tissues of the cerebrum. In some embodiments, the targeted surface or superficial tissue of the cerebrum is located within 4 mm from the surface of the cerebrum. In some embodiments, the targeted surface or superficial tissue of the cerebrum is selected from pial tissue, cerebral cortical ribbon tissue, hippocampus, Virchow-Robbin space, blood vessels in the VR space, hippocampus, parts of the hypothalamus on the underside of the brain, optic nerve and optic tract, olfactory bulb and olfactory process, and combinations thereof.

[0145] In some embodiments, the therapeutic agent (e.g., enzyme) is delivered to one or more deep tissues of the cerebrum. In some embodiments, the targeted surface or superficial tissue of the cerebrum is located below 4 mm (e.g., 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, or 10 mm) from the surface of the cerebrum. In some embodiments, the targeted deep tissue of the cerebrum includes the cerebral cortical ribbon. In some embodiments, the targeted deep tissue of the cerebrum includes one or more of the diencephalon (e.g., hypothalamus, thalamus, ventral thalamus, and ventral thalamus, etc.), hindbrain, lentiform nucleus, basal ganglia, caudate nucleus, putamen, amygdala, globus pallidus, and combinations thereof.

[0146] In some embodiments, the therapeutic agent (e.g., enzyme) is delivered to one or more tissues of the cerebellum. In some embodiments, the one or more target tissues of the cerebellum are selected from the group consisting of molecular layer tissue, Purkinje cell layer tissue, granule cell layer tissue, cerebellar peduncle and combinations thereof. In some embodiments, the therapeutic agent (e.g., enzyme) is delivered to one or more deep tissues of the cerebellum, such as, but not limited to, Purkinje cell layer tissue, granule cell layer tissue, deep cerebellar white matter tissue (e.g., deeper than granule cell layer) and deep cerebellar nucleus tissue.

[0147] In some embodiments, a therapeutic agent (e.g., an enzyme) is delivered to one or more tissues of the brainstem. In some embodiments, the one or more targeted tissues of the brainstem include brainstem white matter tissue and / or brainstem nuclear tissue.

[0148] In some embodiments, therapeutic agents (e.g., enzymes) are delivered to various brain tissues, including, but not limited to, gray matter, white matter, periventricular zone, pia-arachnoid mater, meninges, neocortex, cerebellum, deep tissues of the cerebral cortex, molecular layer, caudate / putamen region, midbrain, deep regions of the pons or medulla oblongata, and combinations thereof.

[0149] In some embodiments, therapeutic agents (e.g., enzymes) are delivered to various cells in the brain, including but not limited to neurons, glial cells, perivascular cells, and / or meningeal cells, hi some embodiments, therapeutic proteins are delivered to oligodendrocytes in the deep white matter. Spinal cord

[0150] Generally, spinal cord regions or tissues can be characterized based on the depth of the tissue, for example, spinal cord tissue can be characterized as superficial or superficial tissue, mid-deep tissue, and / or deep tissue.

[0151] In some embodiments, the therapeutic agent (e.g., an enzyme) is delivered to one or more superficial or superficial tissues of the spinal cord. In some embodiments, the targeted superficial or superficial tissues of the spinal cord are located within 4 mm from the surface of the spinal cord. In some embodiments, the targeted superficial or superficial tissues of the spinal cord include the pia mater and / or white matter tracts.

[0152] In some embodiments, the therapeutic agent (e.g., enzyme) is delivered to one or more deep tissues of the spinal cord. In some embodiments, the targeted deep tissue of the spinal cord is located 4 mm inside from the surface of the spinal cord. In some embodiments, the targeted deep tissue of the spinal cord contains spinal gray matter and / or ependymal cells.

[0153] In some embodiments, a therapeutic agent (eg, an enzyme) is delivered to neurons in the spinal cord. Peripheral target tissue

[0154] As used herein, peripheral organ or tissue refers to any organ or tissue that is not part of the central nervous system (CNS).Peripheral target tissues include, but are not limited to, vasculature, liver, kidney, heart, endothelium, bone marrow and bone marrow-derived cells, spleen, lung, lymph node, bone, cartilage, ovary and testis.In some embodiments, therapeutic protein (e.g., replacement enzyme) according to the present invention is delivered to one or more of peripheral target tissues. Biodistribution and Bioavailability

[0155] In various aspects, once delivered to the target tissue, the therapeutic agent (e.g., I2S enzyme) is localized intracellularly. For example, the therapeutic agent (e.g., enzyme) may be localized to exons, axons, lysosomes, mitochondria, or vacuoles of the target cell (e.g., neurons such as Purkinje cells). For example, in some embodiments, the intrathecally administered enzyme demonstrates transport mechanics such that the enzyme moves into the perivascular space (e.g., by a pulsatile assisted convection mechanism). Additionally, active axonal transport mechanisms involving the association of the administered protein or enzyme with nerve fibers may also contribute to or otherwise facilitate the distribution of the intrathecally administered protein or enzyme into deep tissues of the central nervous system.

[0156] In some embodiments, the therapeutic agent (e.g., replacement enzyme) delivered according to the present invention can achieve therapeutic or clinically effective levels or activities in various target tissues described herein. As used herein, therapeutic or clinically effective levels or activities are sufficient levels or activities to provide therapeutic effects in target tissues. Therapeutic effects can be objective (i.e., measured by some test or marker) or subjective (i.e., subject provides an indication or feeling of effects). For example, therapeutic or clinically effective levels or activities can be enzyme levels or activities that are sufficient to improve symptoms associated with disease (e.g., GAG storage) in target tissues.

[0157] In some embodiments, a therapeutic agent (e.g., replacement enzyme) delivered in accordance with the invention may achieve an enzyme level or activity that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% of the normal level or activity of the corresponding lysosomal enzyme in the target tissue. In some embodiments, a therapeutic agent (e.g., replacement enzyme) delivered in accordance with the invention may achieve an enzyme level or activity that is increased by at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold compared to a control (e.g., endogenous level or activity without treatment). In some embodiments, a therapeutic agent (e.g., replacement enzyme) delivered in accordance with the present invention may achieve an increase in enzyme level or activity in a target tissue of at least about 10 nmol / hr·mg, 20 nmol / hr·mg, 40 nmol / hr·mg, 50 nmol / hr·mg, 60 nmol / hr·mg, 70 nmol / hr·mg, 80 nmol / hr·mg, 90 nmol / hr·mg, 100 nmol / hr·mg, 150 nmol / hr·mg, 200 nmol / hr·mg, 250 nmol / hr·mg, 300 nmol / hr·mg, 350 nmol / hr·mg, 400 nmol / hr·mg, 450 nmol / hr·mg, 500 nmol / hr·mg, 550 nmol / hr·mg, or 600 nmol / hr·mg.

[0158] In some embodiments, the methods of the invention are particularly useful for targeting the lumbar region. In some embodiments, the therapeutic agent (e.g., replacement enzyme) delivered according to the invention can achieve an enzyme level or activity increase in the lumbar region of at least about 500 nmol / hr·mg, 600 nmol / hr·mg, 700 nmol / hr·mg, 800 nmol / hr·mg, 900 nmol / hr·mg, 1000 nmol / hr·mg, 1500 nmol / hr·mg, 2000 nmol / hr·mg, 3000 nmol / hr·mg, 4000 nmol / hr·mg, 5000 nmol / hr·mg, 6000 nmol / hr·mg, 7000 nmol / hr·mg, 8000 nmol / hr·mg, 9000 nmol / hr·mg, or 10,000 nmol / hr·mg.

[0159] In general, the therapeutic agent (e.g., replacement enzyme) delivered according to the present invention has a sufficiently long half-life in the CSF and target tissues of the brain, spinal cord and peripheral organs. In some embodiments, the therapeutic agent (e.g., replacement enzyme) delivered according to the present invention can have a half-life of at least about 30 minutes, 45 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 16 hours, 18 hours, 20 hours, 25 hours, 30 hours, 35 hours, 40 hours, up to 3 days, up to 7 days, up to 14 days, up to 21 days, or up to 1 month. In some embodiments, a therapeutic agent (e.g., replacement enzyme) delivered in accordance with the present invention may retain detectable levels or activity in the CSF or bloodstream 12 hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 ​​hours, 54 hours, 60 hours, 66 hours, 72 hours, 78 hours, 84 hours, 90 hours, 96 hours, 102 hours, or 1 week after administration. Detectable levels or activity may be determined using a variety of methods known in the art.

[0160] In certain embodiments, a therapeutic agent (e.g., replacement enzyme) delivered in accordance with the present invention achieves a concentration of at least 30 μg / ml in the subject's CNS tissues and cells following administration (e.g., 1 week, 3 days, 48 ​​hours, 36 hours, 24 hours, 18 hours, 12 hours, 8 hours, 6 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less following intrathecal administration of a pharmaceutical composition to a subject). In certain embodiments, a therapeutic agent (e.g., replacement enzyme) delivered in accordance with the present invention achieves a concentration in a targeted tissue or cell (e.g., brain tissue or neuron) of a subject of at least 20 μg / ml, at least 15 μg / ml, at least 10 μg / ml, at least 7.5 μg / ml, at least 5 μg / ml, at least 2.5 μg / ml, at least 1.0 μg / ml, or at least 0.5 μg / ml after administration to such subject (e.g., 1 week, 3 days, 48 ​​hours, 36 hours, 24 hours, 18 hours, 12 hours, 8 hours, 6 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, or less after intrathecal administration of such pharmaceutical composition to a subject). Treating Hunter Syndrome and Other Lysosomal Storage Disorders

[0161] Lysosomal storage diseases represent a group of fairly rare inherited metabolic disorders resulting from defects in lysosomal function. Lysosomal diseases are characterized by the accumulation of undigested macromolecular material, including enzyme substrates, within lysosomes (see Table 1), which leads to an increase in the size and number of such lysosomes and, ultimately, cellular dysfunction and clinical abnormalities.

[0162] The methods of the invention described herein can advantageously facilitate the delivery of one or more therapeutic agents (e.g., one or more replacement enzymes) to targeted organelles. For example, lysosomal storage diseases such as Hunter syndrome are characterized by the accumulation of glycosaminoglycans (GAGs) in the lysosomes of affected cells, and therefore lysosomes represent a desirable target organelle for the treatment of lysosomal storage disorders.

[0163] The methods and compositions of the present invention are particularly useful for treating diseases with CNS etiology or components. Examples of lysosomal storage diseases with CNS etiology or components include, but are not limited to, Sanfilippo syndrome type A, Sanfilippo syndrome type B, Hunter syndrome, metachromatic leukodystrophy and globoid cell leukodystrophy. Prior to the present invention, traditional therapies were limited to being administered intravenously to subjects and were generally only effective in treating the somatic symptoms of the underlying enzyme deficiency. The compositions and methods of the present invention can be beneficially administered directly into the CNS of subjects suffering from such diseases with CNS etiology, thereby achieving therapeutic concentrations in affected cells and tissues of the CNS (e.g., brain), thus overcoming the limitations associated with traditional systemic administration of such therapeutic agents.

[0164] In some embodiments, the methods and compositions of the present invention are useful for treating both the neurological and somatic sequelae or syndromes of lysosomal storage disorders.For example, some embodiments of the present invention relate to compositions and methods for delivering one or more therapeutic agents to the CNS of a subject (e.g., intrathecally, intravenously, or intracisternally) for treating CNS or neurological sequelae and manifestations of lysosomal storage disorders, while also treating the systemic or somatic manifestations of the lysosomal storage disorders.For example, some compositions of the present invention are administered intrathecally to a subject, thereby delivering one or more therapeutic agents to the CNS of a subject to treat neurological sequelae, and conversely, one or more therapeutic agents are administered intravenously to deliver such therapeutic agents to both the cells and tissues of the systemic circulation (e.g., cells and tissues of the heart, lungs, liver, kidneys, or lymph nodes), thereby treating somatic sequelae. For example, a subject having or otherwise affected by a lysosomal storage disease (e.g., Hunter syndrome) may be administered a pharmaceutical composition containing one or more therapeutic agents (e.g., iduronate-2-sulfatase) intrathecally at least once a week, once every two weeks, once a month, once every two months or more to treat neurological sequelae, while a different therapeutic agent may be administered intravenously to the subject on a more frequent basis (e.g., once a day, once every other day, three times a week or once a week) to treat systemic or somatic manifestations of the disease.

[0165] Hunter syndrome, or mucopolysaccharidosis II (MPS II), is an X-linked inherited metabolic disorder caused by deficiency of the enzyme iduronate-2-sulfatase (I2S). I2S is localized to lysosomes and plays a key role in the catabolism of the glycosaminoglycans (GAGs) heparin and dermatan sulfate. In the absence of the enzyme, these substances accumulate intracellularly, eventually causing hyperemia, followed by cell death and tissue destruction. Due to widespread expression of the enzyme, multiple cell types and organ systems are affected in MPS II patients.

[0166] The defining clinical feature of this disorder is central nervous system (CNS) degeneration, which results in cognitive impairment (e.g., reduced IQ). In addition, MRI scans of affected individuals have distinct white matter lesions; dilated perivascular spaces in the brain parenchyma, ganglia, corpus callosum, and brain stem; atrophy; and ventricular enlargement (Wang et al., Molecular Genetics and Metabolism, 2009). The disease typically manifests several years after birth with organomegaly and skeletal abnormalities. Most affected individuals die from disease-related complications by age 10 or 20, while some experience a progressive decline in cognitive function.

[0167] The compositions and methods of the present invention can be used to effectively treat individuals affected by or susceptible to Hunter Syndrome. As used herein, the term "treat" or "treatment" refers to alleviating one or more symptoms associated with a disease, inhibiting or delaying the onset of one or more symptoms of a disease, and / or reducing the severity or frequency of one or more symptoms of a disease.

[0168] In some embodiments, treatment refers to partial or complete relief, alleviation, sedation, delay in onset, reduction in severity and / or incidence of neurological disorders in Hunter syndrome patients.As used herein, the term "neurological disorders" includes various symptoms related to disorders of the central nervous system (e.g., brain and spinal cord).Symptoms of neurological disorders include, for example, cognitive impairment; white matter lesions; dilated perivascular spaces in brain parenchyma, ganglion, corpus callosum, and / or brain stem; atrophy; and / or ventricular enlargement.

[0169] In some embodiments, treatment refers to the reduction of lysosomal accumulation (e.g., of GAGs) in various tissues. In some embodiments, treatment refers to the reduction of lysosomal accumulation in brain target tissues, spinal cord neurons, and / or peripheral target tissues. In some embodiments, lysosomal accumulation is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more compared to control. In some embodiments, lysosomal accumulation is reduced by at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold compared to control. In some embodiments, lysosomal accumulation is measured by the presence of lysosomal storage granules (e.g., zebra stripe shape). The presence of lysosomal storage granules can be determined by a variety of methods known in the art, such as by histological analysis.

[0170] In some embodiments, treatment refers to a reduction in vacuolation in neurons (e.g., neurons containing Purkinje cells). In some embodiments, the vacuolation in neurons is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more compared to a control. In some embodiments, the vacuolation is reduced by at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold or 10-fold compared to a control. The presence and reduction of vacuolation can be measured by various methods known in the art, such as by histological analysis.

[0171] In some embodiments, treatment refers to increasing I2S enzyme activity in various tissues. In some embodiments, treatment refers to increasing I2S enzyme activity in brain target tissues, spinal cord neurons, and / or peripheral target tissues. In some embodiments, I2S enzyme activity is increased by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more compared to a control. In some embodiments, I2S enzyme activity is increased by at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold compared to a control. In some embodiments, the increased I2S enzyme activity is at least about 10 nmol / hr·mg, 20 nmol / hr·mg, 40 nmol / hr·mg, 50 nmol / hr·mg, 60 nmol / hr·mg, 70 nmol / hr·mg, 80 nmol / hr·mg, 90 nmol / hr·mg, 100 nmol / hr·mg, 150 nmol / hr·mg, 200 nmol / hr·mg, 250 nmol / hr·mg, 300 nmol / hr·mg, 350 nmol / hr·mg, 400 nmol / hr·mg, 450 nmol / hr·mg, 500 nmol / hr·mg, 550 nmol / hr·mg, 600 nmol / hr·mg or more. In some embodiments, the I2S enzyme activity is increased in the lumbar region or in cells of the lumbar region. In some embodiments, increased I2S enzyme activity in the lumbar region is at least about 2000 nmol / hr·mg, 3000 nmol / hr·mg, 4000 nmol / hr·mg, 5000 nmol / hr·mg, 6000 nmol / hr·mg, 7000 nmol / hr·mg, 8000 nmol / hr·mg, 9000 nmol / hr·mg, 10,000 nmol / hr·mg or more, hi some embodiments, I2S enzyme activity is increased in the distal spinal cord or in cells of the distal spinal cord.

[0172] In some embodiments, treatment refers to reducing the progression of cognitive loss. In some embodiments, the progression of cognitive loss is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more compared to a control. In some embodiments, treatment refers to reducing developmental delay. In some embodiments, the developmental delay is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more compared to a control.

[0173] In some embodiments, treatment refers to increased survival (e.g., survival time). For example, treatment may result in an increase in the patient's life expectancy. In some embodiments, treatment according to the invention increases the life expectancy of a patient by more than about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or more than about 5% compared to the life expectancy of one or more control individuals with a similar disease without treatment. Increases the patient's life expectancy by about 95%, about 100%, about 105%, about 110%, about 115%, about 120%, about 125%, about 130%, about 135%, about 140%, about 145%, about 150%, about 155%, about 160%, about 165%, about 170%, about 175%, about 180%, about 185%, about 190%, about 195%, about 200% or more. In some embodiments, treatment according to the present invention increases the patient's life expectancy by more than about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years or more, as compared to the life expectancy of one or more control individuals with a similar disease without treatment. In some embodiments, treatment according to the invention results in long-term survival of the patient. As used herein, the term "long-term survival" refers to a survival time or life expectancy of about 40, 45, 50, 55, 60 years or more.

[0174] The terms "improve," "increase," or "reduce," as used herein, refer to values ​​relative to a control. In some embodiments, a suitable control is a baseline measurement, e.g., a measurement in the same individual before the initiation of a treatment described herein, or a measurement in a control individual (or multiple control individuals) in the absence of a treatment described herein. A "control individual" is an individual suffering from the same disease who is approximately the same age and / or sex as the individual being treated (to ensure that the stage of the disease in the treated and control individual(s) is comparable).

[0175] The individual to be treated (also referred to as a "patient" or "subject") is an individual (fetus, infant, adolescent, or adult) who has Hunter syndrome or has the potential to develop Hunter syndrome. The individual may have residual endogenous I2S protein expression and / or activity, or may have no measurable activity. For example, an individual with Hunter syndrome may have an I2S expression level that is less than about 30-50%, less than about 25-30%, less than about 20-25%, less than about 15-20%, less than about 10-15%, less than about 5-10%, or less than about 0.1-5% of the normal I2S expression level.

[0176] In some embodiments, the individual is one who has recently been diagnosed with the disease. Typically, early treatment (starting treatment as soon as possible after diagnosis) is important to minimize the effects of the disease and maximize the benefits of treatment. Immune tolerance

[0177] In general, intrathecal administration of therapeutic agents (e.g., replacement enzymes) according to the present invention does not cause severe side effects in subjects. As used herein, severe side effects include, but are not limited to, inducing substantial immune responses, toxicity, or death. As used herein, the term "substantial immune response" refers to severe or severe immune responses, such as adaptive T cell immune responses.

[0178] Thus, in many embodiments, the methods of the invention do not include concurrent immunosuppressant therapy (i.e., any immunosuppressant therapy used as pretreatment / preconditioning or in parallel with the method). In some embodiments, the methods of the invention do not include immune tolerance induction in the subject being treated. In some embodiments, the methods of the invention do not include pretreatment or preconditioning of the subject with a T cell immunosuppressant.

[0179] In some embodiments, intrathecal administration of therapeutic agents may enhance the immune response to these agents. Thus, in some embodiments, it may be useful to vaccinate patients with supplemental enzymes that are tolerant to enzyme support therapy. Immune tolerance may be induced using a variety of methods known in the art. For example, an initial 30-60 day regimen of a T cell immunosuppressant, such as cyclosporine A (CsA), and an antiproliferative agent, such as azathioprine (Aza), combined with weekly intrathecal infusions of low doses of the desired replacement enzyme may be used.

[0180] Any immunosuppressant known to one of ordinary skill in the art may be used together with the combination therapy of the present invention. Such immunosuppressants include cyclosporine, FK506, rapamycin, CTLA4-Ig, and anti-TNF agents, such as etanercept (see, e.g., Modern, 2000, Ann. Allergy Asthma Immunol. 84, 280-284; Nevins, 2000, Curr. Opin. Pediatr. 12, 146-150; Kurlberg et al., 2000, Scand. J. Immunol. 51, 224-230; Ideguchi et al., 2000, Neuroscience 95, 217-226; Potteret al., 1999, Ann. NY Acad. Sci. 875, 159-174; Slavik et al., 1999, Immunol. Res. 19, 1-24; Gaziev et al., 2000, Neuroscience 95, 217-226). al., 1999, Bone Marrow Transplant. 25, 689-696;Henry, 1999, Clin. Transplant. 13, 209-220;Gummert et al., 1999, J. Am. Soc. Nephrol. 10, 1366-1380;Qi et al., 2000, Transplantation 69, 1275-1283).Anti-IL2 receptor (alpha-subunit) antibody daclizumab (e.g., Zenapax TM), which has been demonstrated to be effective in transplant patients, may also be used as an immunosuppressant (e.g., Wiseman et al., 1999, Drugs 58, 1029-1042;Beniaminovitz et al., 2000, N. Engl J. Med. 342, 613-619;Ponticelli et See, e.g., Berard et al., 1999, Drugs RD 1, 55-60; Berard et al., 1999, Pharmacotherapy 19, 1127-1137; Eckhoff et al., 2000, Transplantation 69, 1867-1872; Ekberg et al., 2000, Transpl. Int. 13, 151-159). Additional immunosuppressive agents include anti-CD2 (Branco et al., 1999, Transplantation 68, 1588-1596;Przepiorka et al., 1998, Blood 92, 4066-4071), anti-CD4 (Marinova-Mutafchieva et al., 2000, Arthritis Rheum. 43, 638-644;Fishwild et al., 1999, Clin. Immunol. 92, 138-152) and anti-CD40 ligand (Hong et al., 2000, Semin. Nephrol. 20, 108-125; Chirmule et al., 2000, J. Virol. 74, 3345-3352; Ito et al., 2000, J. Immunol. 164, 1230-1235). Administration

[0181] The method of the present invention contemplates single and multiple administration of therapeutically effective amount of the therapeutic agent (e.g., replacement enzyme) described herein. The therapeutic agent (e.g., replacement enzyme) can be administered at regular intervals depending on the nature, severity and extent of the subject's condition (e.g., lysosomal storage disease). In some embodiments, the therapeutically effective amount of the therapeutic agent (e.g., replacement enzyme) of the present invention can be administered intrathecally periodically at regular intervals (e.g., once a year, once every 6 months, once every 5 months, once every 3 months, every other month (once every 2 months), monthly (once a month), every other week (once every 2 weeks), weekly).

[0182] In some embodiments, intrathecal administration may be used in conjunction with other routes of administration (e.g., intravenous, subcutaneous, intramuscular, parenteral, transdermal, or intramuscular (e.g., orally or nasally)). In some embodiments, other routes of administration (e.g., intravenous administration) may be performed biweekly, monthly, once every two months, once every three months, once every four months, once every five months, once every six months, annually or less. In some embodiments, the method further comprises administering an I2S replacement enzyme to the subject. In some embodiments, intravenous administration is no more frequent than weekly (e.g., no more frequent than every two weeks, monthly, once every two months, once every three months, once every four months, once every five months, or once every six months). In some embodiments, intravenous administration is no more frequent than monthly, such as twice weekly, weekly, biweekly, or monthly. In some embodiments, intravenous and intrathecal administration are performed on the same day. In some embodiments, intravenous and intrathecal administration are not performed within a certain time of each other, such as not within at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, or at least 1 week. In some embodiments, intravenous and intrathecal administration are performed in an alternating dosing schedule, such as monthly, biweekly, twice monthly, or monthly alternating dosing. In some embodiments, intrathecal administration is substituted for intravenous administration in a dosing schedule, such as monthly, biweekly, twice monthly, or monthly intravenous administration, and every third or fourth or fifth dose in this schedule can be replaced with intrathecal administration instead of intravenous administration. In some embodiments, intravenous administration is substituted for intrathecal administration in a dosing schedule, such as monthly, biweekly, twice monthly, or monthly intrathecal administration, and every third or fourth or fifth dose in this schedule can be replaced with intravenous administration instead of intrathecal administration.In some embodiments, the intravenous and intrathecal administrations are performed sequentially, such as by administering the intravenous administration first (e.g., weekly, biweekly, twice monthly, or monthly for 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year or more), followed by the intrathecal administration (e.g., weekly, biweekly, twice monthly, or monthly for 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year or more). In some embodiments, intrathecal administration is performed first (e.g., weekly, biweekly, twice monthly, or monthly for 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year or more), followed by intravenous administration (e.g., weekly, biweekly, twice monthly, or monthly for 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year or more).

[0183] In some embodiments, Hunter syndrome is associated with peripheral symptoms and the method includes administering a replacement enzyme intrathecally but not intravenously to the subject. In some embodiments, intrathecal administration of an I2S enzyme ameliorates or reduces one or more peripheral symptoms associated with I2S deficiency in the subject.

[0184] As used herein, the term "therapeutically effective amount" is determined mainly based on the total amount of therapeutic agent contained in the pharmaceutical composition of the present invention. Generally, a therapeutically effective amount is sufficient to achieve a meaningful benefit to the subject (e.g., treat, regulate, cure, prevent, and / or improve the underlying disease or symptoms). For example, a therapeutically effective amount can be an amount sufficient to achieve a desired therapeutic and / or preventive effect, such as an amount sufficient to regulate lysosomal enzyme receptors or their activity, thereby treating such lysosomal storage disease or its symptoms (e.g., reduce or eliminate the presence or appearance of "zebra bodies" or cell vacuolation after administering the composition of the present invention to the subject). Generally, the amount of therapeutic agent (e.g., recombinant lysosomal enzyme) administered to a subject in need thereof depends on the characteristics of the subject. Such characteristics include the symptoms, disease severity, general health, age, sex, and weight of the subject. Depending on these and other related factors, the appropriate dosage can be easily determined by those skilled in the art. In addition, both objective and subjective tests may optionally be used to identify optimal dosage ranges.

[0185] The therapeutically effective amount is generally administered in a dosage regimen that may include multiple unit doses.For any particular therapeutic protein, the therapeutically effective amount (and / or the appropriate unit dose within the effective dosage regimen) may vary, for example, by route of administration, combination with other pharmaceutical agents.Furthermore, the specific therapeutically effective amount (and / or unit dose) for any particular patient may depend on various factors, such as the disorder being treated and the severity of the disorder; the activity of the specific pharmaceutical agent used; the specific composition used; the age, weight, general health, sex and diet of the patient; the time of administration; the route of administration, and / or the excretion or metabolic rate of the specific fusion protein used; the duration of treatment; and factors that are well known in the medical industry.

[0186] In some embodiments, the therapeutically effective dose is about 0.005 mg / kg brain to 500 mg / kg brain, e.g., about 0.005 mg / kg brain to 400 mg / kg brain, about 0.005 mg / kg brain to 300 mg / kg brain, about 0.005 mg / kg brain to 200 mg / kg brain, about 0.005 mg / kg brain to 100 mg / kg brain, about 0.005 mg / kg brain to 90 mg / kg brain, about 0.005 mg / kg brain to 80 mg / kg brain, about 0.005 mg / kg brain to 10 ... g to 70 mg / kg of brain, about 0.005 mg / kg to 60 mg / kg of brain, about 0.005 mg / kg to 50 mg / kg of brain, about 0.005 mg / kg to 40 mg / kg of brain, about 0.005 mg / kg to 30 mg / kg of brain, about 0.005 mg / kg to 25 mg / kg of brain, about 0.005 mg / kg to 20 mg / kg of brain, about 0.005 mg / kg to 15 mg / kg of brain, about 0.005 mg / kg to 10 mg / kg of brain.

[0187] In some embodiments, the therapeutically effective dose is greater than about 0.1 mg / kg brain, greater than about 0.5 mg / kg brain, greater than about 1.0 mg / kg brain, greater than about 3 mg / kg brain, greater than about 5 mg / kg brain, greater than about 10 mg / kg brain, greater than about 15 mg / kg brain, greater than about 20 mg / kg brain, greater than about 30 mg / kg brain, greater than about 40 mg / kg brain, greater than about 50 mg / kg brain, greater than about 60 mg / kg brain, greater than about 70 mg / kg brain, greater than about 80 mg / kg brain, greater than about 90 mg / kg brain, greater than about 100 mg / kg brain, greater than about 150 mg / kg brain, greater than about 20 mg / kg brain, greater than about 30 mg / kg brain, greater than about 40 mg / kg brain, greater than about 50 mg / kg brain, greater than about 60 mg / kg brain, greater than about 100 mg / kg brain, greater than about 15 ...60 mg / kg brain, greater than about 170 mg / kg brain, greater than about 180 mg / kg brain, greater than about 180 mg / kg brain, greater than about kg, greater than about 70 mg / kg brain, greater than about 80 mg / kg brain, greater than about 90 mg / kg brain, greater than about 100 mg / kg brain, greater than about 150 mg / kg brain, greater than about 200 mg / kg brain, greater than about 250 mg / kg brain, greater than about 300 mg / kg brain, greater than about 350 mg / kg brain, greater than about 400 mg / kg brain, greater than about 450 mg / kg brain, greater than about 500 mg / kg brain.

[0188] In some embodiments, the therapeutically effective dose may also be defined by mg / kg body weight. As one of skill in the art will appreciate, brain weight and body weight may be correlated (Dekaban AS. "Changes in brain weights during the span of human life: relation of brain weights to body heights and body weights," Ann Neurol 1978; 4:345-56). Thus, in some embodiments, dosages may be calculated as shown in Table 5. [Table 5]

[0189] In some embodiments, the therapeutically effective dose may also be defined by mg / 15cc of CSF. As those skilled in the art will appreciate, the therapeutically effective dose based on brain weight and body weight may be converted to mg / 15cc of CSF. For example, the volume of CSF in an adult is about 150mL (Johanson CE, et al. "Multiplicity of cerebrospinal fluid functions: New challenges in health and disease," Cerebrospinal Fluid Res. 2008 May 14;5:10). Thus, a single dose injection of 0.1mg to 50mg into an adult is about a 0.01mg / 15cc (0.1mg) to 5.0mg / 15cc (50mg) dose in an adult.

[0190] It is to be further understood that for any particular subject, specific dosage regimens will be adjusted over time according to the individual needs and the professional judgment of the person administering or directing the administration of enzyme replacement therapy, and that the dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the invention. kit

[0191] The present invention further provides kits or other products containing the formulations of the present invention, and provide equipment for their reconstitution (when lyophilized) and / or use. Kits or other products may include containers, IDDDs, catheters, and any other materials, devices, or equipment useful for intrathecal administration and related surgical procedures. Suitable containers include, for example, bottles, vials, syringes (pre-filled syringes), ampoules, cartridges, reservoirs, or lyo-jects. Containers may be made of various materials, such as glass or plastic. In some embodiments, the container is a pre-filled syringe. Suitable pre-filled syringes include, but are not limited to, borosilicate glass syringes with baked silicone coating, borosilicate glass syringes with sprayed silicone, or plastic resin syringes that do not contain silicone.

[0192] Typically, the container may hold the formulation, as well as a label on or associated with the container that may indicate instructions for reconstitution and / or use. For example, the label may indicate that the formulation is reconstituted to a protein concentration as described above. The label may further indicate that the formulation is useful or intended for, for example, IT administration. In some embodiments, the container may contain a single dose of a stable formulation containing a therapeutic agent (e.g., replacement enzyme). In various embodiments, the single dose of the stable formulation is present in a volume of less than about 15 ml, 10 ml, 5.0 ml, 4.0 ml, 3.5 ml, 3.0 ml, 2.5 ml, 2.0 ml, 1.5 ml, 1.0 ml, or 0.5 ml. Alternatively, the container holding the formulation may be a multi-use vial, which may allow for repeated administration (e.g., 2-6 administrations) of the formulation. The kit or other product may further include a second container containing a suitable diluent (e.g., BWFI, saline, buffered saline). Upon mixing of the diluent and formulation, the final protein concentration in the reconstituted formulation is generally at least 1 mg / ml (e.g., at least 5 mg / ml, at least 10 mg / ml, at least 25 mg / ml, at least 50 mg / ml, at least 75 mg / ml, at least 100 mg / ml). The kit or other article of manufacture may further include other materials desirable from a commercial and user standpoint, such as other buffers, diluents, fillers, needles, IDDDs, catheters, syringes, and package inserts with instructions for use.

[0193] The present invention will be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the invention. All cited references are incorporated herein by reference. EXAMPLES

[0194] Example 1: Biodistribution The primary objective of this study was to determine whether recombinant human I2S could be delivered to the brain of adult MPS II mice by the intrathecal-lumbar route. [Table 6] material and method animal:

[0195] Mice were housed in groups of up to four per cage in a colony room under a 12-hour light / dark cycle. Rodent chow (LabDiet-5001, St. Louis, MO) and water (Lexington, MA public water purified by reverse osmosis) were available ad libitum for the duration of the experiment. Animal care was performed in accordance with the guidelines described in the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington DC, 1996). The current IKO breeding colony was established from four carrier female mice heterozygous for the IKO mutation, provided by Dr. Joseph Muenzer (University of North Carolina). Carrier females were bred to male mice on a C57BL / 6 background (C57BL / 6NTac, Taconic, Hudson, NY) to generate heterozygous female and hemizygous male knockout mice, as well as wild-type male and female littermates. All offspring were genotyped by PCR analysis of tissue DNA. All mice used in this experiment were males identified as either hemizygous IKO (- / 0) or wild-type (WT) littermates (+ / 0) between 8 and 12 weeks of age. Idulsulfase

[0196] 22 mL of I2S (recombinant human idursulfase) was dialyzed against four changes of 2 L of phosphate buffered saline. I2S was then concentrated by Vivaspin column and resuspended in a final volume of 1 mL of PBS, followed by filter sterilization using a 0.2 μm filter. The final concentration was 51 mg / mL. Intrathecal-lumbar injection:

[0197] Adult mice were anesthetized with 1.25% 2,2,2-tribromoethanol (Avertin) at 200–300 μL / 10 g body weight (250–350 mg / kg) via intraperitoneal injection. Dorsal hair was removed from the base of the tail to the scapula, and the clipped area was swabbed with a povidine / betadine scrub followed by isopropyl alcohol. A small midline skin incision (1–2 cm) was made over the lumbosacral spine, and the intersection of the dorsal midline with the cranial side of the iliac wing (iliac singularity) was identified. The muscle within the iliac fossa (gluteus medius) is a heart-shaped muscle, and either side of the top of the "heart" approximates the location of the iliac wing. A 32-gauge needle attached to an airtight 10–20 μL glass Hamilton syringe was inserted until resistance was felt from the underlying bone. Injections of 10 μL of test article were made at a rate of approximately 2 μL / 20 sec (10 μL / 2 min). Skin incisions were closed appropriately using wound clips and animals were allowed to recover in a recovery room before being returned to their appropriate cages. Histological processing

[0198] The animals were sacrificed 1 hour after the final injection.

[0199] Brain and liver tissues were harvested and fixed in 10% neutral buffered formalin, then processed and embedded in paraffin. 5 μm sections were prepared for hematoxylin / eosin (H&E) and immunohistochemistry (IHC) staining. Hematoxylin and eosin staining:

[0200] Brain and liver sections were stained with H&E. The staining results showed nuclei as purple and cytoplasm as pink to red. H&E stained slides were used for histopathological and morphological evaluation. Immunohistochemistry:

[0201] For I2S biodistribution assessment, deparaffinized and rehydrated brain and liver sections were incubated overnight with mouse monoclonal antibody 2C4-2B2 against recombinant human I2S (Maine Biotechnology Services, Portland, ME) (or irrelevant mouse IgG as a negative control antibody; Vector Laboratories, Burlingame, CA) to detect injected I2S. After overnight incubation at 2–8°C, a secondary goat anti-mouse IgG conjugated to horseradish peroxidase was added. After an additional 30 min incubation at 37°C, Tyramide-Alexa Fluor 488 labeling solution (Invitrogen Corp., Carlsbad, CA) was added for an additional 10 min. Sections were coverslipped with antifading mounting medium (VectaShield; Vector Laboratories) containing 1.5 μg / ml 4'-6-diamminediino-2-phenylindole (DAPI) as a nuclear counterstain and viewed under a multichannel Nikon fluorescence microscope. Staining results showed I2S-positive cells in green, nuclei in blue, and background areas in black.

[0202] For effective analysis, brain and liver sections were stained with rat anti-LAMP-1 (lysosomal associated membrane protein as a lysosomal marker) IgG (Santa Cruz Biotechnology, Santa Cruz, California) as the primary antibody. Rat IgG as an irrelevant antibody was used as a negative control. The ABC (avidin-biotin complex kit obtained from Vector Labs, Burlingame, California) method was used to amplify the target markers.

[0203] Briefly, deparaffinized sections were rehydrated and incubated with primary antibodies. After overnight incubation at 2–8°C, secondary biotinylated rabbit anti-rat IgG (Vector Labs, Burlingame, California) was added and incubated at 37°C for 30 min, and then samples were washed and treated with avidin-biotin-peroxidase complex (Vector Laboratories) for 30 min. For color development, 3,3′-diaminobenzidine (DAB) tetrahydrochloride was used as a chromogen. Sections were then counterstained with hematoxylin and coverslipped. Staining results showed LAMP-1 positive cells in brown and nuclei in blue.

[0204] Representative photographs were taken, and the areas of LAMP-1 positive cells were analyzed with Image-Pro Plus software (Media Cybernetics. Inc., Bethesda, MD), and comparative statistics were performed using Student's t test. Electron microscopy:

[0205] Brain tissue from animals treated with three doses of I2S was fixed overnight at 4° C. in 2.5% PFA / 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4. Samples were then washed in cacodylate buffer (0.1 M, pH 7.4), post-fixed in osmium tetroxide, dehydrated in alcohol and propylene oxide, and embedded in Epon resin. Ultrathin sections were cut at 100 nm, stained with lead citrate, and stained with Tecnai® G. 2 Observation was performed using a Spirit BioTWIN transmission electron microscope. result

[0206] In the brain, I2S was not observed in vehicle control animals as determined by immunohistochemistry (IHC) staining. In contrast, in I2S-injected animals, meningeal cells, cerebral and cerebellar neurons stained positive for I2S. The staining signal was stronger in animals administered the three doses (Figure 1).

[0207] In the brain tissue of vehicle-treated IKO mice, cellular vacuolization, a histopathological hallmark of lysosomal storage disease, was noted throughout the brain compared to wild-type animals. In I2S-treated IKO mice, there was a widespread reduction in cellular vacuolization from the superficial cerebral cortex, caudate nucleus, thalamus, cerebellum to the white matter compared to untreated mice (Figure 2). Abnormally high lysosomal activity was noted in microglia, meningeal cells, and perivascular cells in vehicle-treated IKO mice by lysosomal-associated membrane protein-1 (LAMP-1) staining, an indicator of lysosomal activity and disease state, when compared to wild-type animals. I2S intrathecally treated mice had a significant reduction in LAMP-1 immunostaining. This reduction was characterized by a decrease in the number and brighter staining of LAMP-1 positive cells. This reduction was noted throughout the brain from the superficial cerebral cortex, caudate nucleus, thalamus, cerebellum to the white matter in both 2-dose and 3-dose I2S-treated animals (Figure 3). Morphometric analysis of LAMP-1 immunostaining of various brain regions confirmed that there was a significant reduction in LAMP-1 immunostaining-positive staining in all brain regions evaluated (Figure 4).

[0208] Electron microscopy of vehicle-treated IKO mice revealed enlarged vacuoles containing amorphous granular storage material and inclusion bodies with plate-like, zebra body-like structures. These typical pathological features of lysosomal storage at the ultrastructural level were reduced in mice intrathecally-lumbar-injected with I2S (Figure 5).

[0209] In the liver, there was no positive staining for I2S in vehicle-treated animals. In I2S intrathecally injected mice, a large amount of injected I2S was clearly found in the sinusoidal cells (Figure 6), indicating that I2S injected into the intrathecal space circulated with the CSF and was then absorbed into the circulation via the arachnoid granules.

[0210] In the liver tissues of vehicle-treated IKO mice, severe cellular vacuolization and abnormally high lysosomal activity as well as strong LAMP-1 immunostaining were confirmed by H&E staining compared to WT mice. A marked decrease in intracellular vacuolization and LAMP-1 immunostaining in the liver was confirmed after intrathecal treatment with I2S. H&E staining showed that intracytoplasmic vacuolization almost completely disappeared, resembling normal liver cell structure (Figure 7).

[0211] In IKO mice, recombinant human I2S is delivered to the brain by the intrathecal-lumbar route, and injected I2S produces widespread histopathological improvements in various regions of the brain. The injected I2S was detected in meningeal cells and brain neurons. Decreased cellular vacuolization throughout the brain at both light and electron microscopic levels. - Reduction of LAMP-1 lysosomal marker throughout the brain. Intrathecally injected I2S entered the peripheral circulation and improved morphological and histological markers in the liver. Example 2: Toxicity

[0212] This example demonstrates the clinical signs associated with monthly bolus intrathecal lumbar administration of idursulfase in cynomolgus monkeys. To accomplish this, 14 male cynomolgus monkeys were randomized into 5 treatment groups, as shown in the table below. [Table 7]

[0213] Animals in all groups were dosed IT three times at monthly intervals at the level of the lumbar spine. The dose volume of 1 ml was flushed from the catheter system with 0.3 ml of PBS. Approximately 2 mL of CSF was collected from an IT spinal puncture at the level of the cisterna magna 1-2 days before each dose. Blood samples (2 ml) were also collected at this time. Blood (2 ml) and CSF (0.1 ml) were collected from animals in the five groups pre-dose, 0.5, 1, 2, 4, 8, 24, and 48 hours after the first dose. Clinical signs were recorded twice daily. Necropsy was performed approximately 24 hours after the third dose, and selected tissues were collected and preserved.

[0214] On Day 1, all 3 animals in Group 4 (150 mg) showed minimal hindquarter tendencies within 3-12 minutes post-dose that lasted for 5-15 minutes and were considered test article related. There were no changes in body weight, food consumption, or neurological / physical examination parameters considered test article related.

[0215] Analysis of serum and CSF samples as well as dosing solution analysis are shown. Variation in endogenous idursulfase activity was observed in different tissues from cynomolgus monkeys, with the brain and spinal cord having greater endogenous activity than other peripheral organs tested, including the liver, heart, and kidney. Idursulfase administration was associated with a dose-dependent increase in idursulfase activity in various brain regions, as well as in the brain stem and spinal cord. IT delivery did not result in observable differences in distribution between the right and left cerebral hemispheres. There was a clear dose-dependent increase in idursulfase activity in the following organs: brain, liver, heart, and kidney. Immunostaining for idursulfase in the brain demonstrated a dose-dependent increase in staining intensity. In the 3 mg group, meningeal cell staining and limited glial cell staining below the meninges was observed, and neuronal staining was not evident in animals from the 3 mg treatment group. Idursulfase staining was positive and dose-dependent in the spinal cord, with very high staining intensity in the lumbar region, where IT administration of idursulfase occurred. Idursulfase staining intensity in the liver, kidney, and heart was dose-dependent, consistent with increased idursulfase activity in these organs.

[0216] In conclusion, IT administration of idursulfase at doses up to 150 mg at monthly intervals had no side effects. The no observed adverse effect level (NOAEL) was therefore taken to be 150 mg, the highest dose tested in this study. Idursulfase administration was associated with a dose-dependent increase in idursulfase activity in the CNS, resulting in systemic I2S levels and activity in the liver, kidney, and heart.

[0217] The test article, idursulfase, was supplied in 154 mM NaCl, 0.005% polysorbate 20, pH 5.3-6.1. The nominal concentrations of the dosing solutions supplied were 0, 3, 30, or 150 mg / ml. Test articles were stored in a freezer at -82 to -79°C. Phosphate buffered saline (PBS), pH 7.2, was used as a flushing agent after the dose was administered as well as after the serial CSF was collected. The PBS was obtained from Gibco, Invitrogen Corporation. Preparation of test substance dosage

[0218] On the first day of dosing for each time interval, one vial of each concentration was removed from the -80°C freezer and thawed to room temperature on the bench. Once thawed, vials for groups 1, 2, and 3 were labeled, weighed, and 1 ml was withdrawn through a 0.22 μm filter for each animal in the dosing schedule. After all doses had been administered, the vials were reweighed and placed in the freezer.

[0219] The next day (dosing day for Animal 003, Groups 4 and 5), the dosing solutions for Groups 1 and 4 were removed from the freezer and placed on the bench and allowed to reach room temperature. Once at room temperature, the vials for Groups 1 and 4 were weighed, the Group 4 vial was labeled, and 1 ml was withdrawn through the filter for each animal scheduled to receive Groups 1 and 4. The dosing solution for Group 5 was then prepared by injecting the appropriate amount of Group 4 dosing solution and Group 1 (vehicle) into a sterile polypropylene vial. The amount added from Groups 1 and 4 was recorded. The solutions were mixed by gently inverting the vial, and 2-1 ml doses were withdrawn through the filter for the animals in Group 5. Upon completion of dosing, the vials for Groups 1 and 4 were reweighed and all vials (Groups 1-5) were placed in the freezer.

[0220] Fourteen animals were randomized into treatment groups as described in the table below.

[0221] The IT route of administration was chosen because this is the intended route for human administration. The doses of idursulfase selected for this study (3, 30, 100, and 150 mg / ml) were chosen to evaluate the biodistribution of varying dose levels of the enzyme within the non-human primate central nervous system (CNS) following three consecutive monthly bolus IT lumbar injections. Clinical Observations

[0222] The overall incidence of clinical signs was minimal: no animals in Groups 1 (control), 2 (3 mg), 3 (30 mg), or 5 (100 mg) had clinical signs considered to be related to the test article at any time during the study.

[0223] On Day 1, all three animals (012-014) in Group 4 (150 mg) showed a minimal tendency for hindquarters within 3-12 minutes of dosing and lasting for 5-15 minutes. This sign was believed to be test substance related and was not observed in any of the lower dose groups. No other clinical signs were noted immediately following the first dose or on the days immediately following test substance administration. The only other sign observed for Group 4 animals was a single episode of vomiting in Animal 013 on Day 35.

[0224] Administration of the test article as a single monthly intrathecal bolus was not associated with any adverse gross or microscopic changes when taking into account the inherent changes due to the inserted drug delivery device. All groups, including the control group, had microscopic changes in the meninges indicative of an inflammatory response to the drug delivery system. In animals receiving doses of 30 mg or greater of the test article, the inflammatory response in the meninges tended to have a more pronounced eosinophilic component.

[0225] The differences between control and test substance treated animals were so small that the no observed adverse effect level (NOAEL) was taken to be 150 mg, the highest dose tested in this study.

[0226] The overall inflammatory response in the meninges in all groups (including controls) was slightly less pronounced than that generally occurring in intrathecal studies of this duration in monkeys, however this may be related to some properties of the vehicle or to an effect of the dose administered 24 hours prior to necropsy.

[0227] Brain idursulfase staining was positive in all treated animals except one animal in the 3 mg group, with the highest staining intensity observed in the 150 mg group (Figures 16, 17, 18 and 19). In the 3 mg group, only meningeal cells and a few glial cells beneath the meningeal cells were positive, and injected idursulfase was not detected in neurons. In the higher dose groups (30, 100 and 150 mg), in addition to meningeal cells, glial cells and perivascular cells, a large population of intracerebral neurons was positive for idursulfase staining. Idursulfase immunostaining revealed widespread distribution of injected idursulfase in intracerebral neurons, from neurons in layer I superficially near the meninges to neurons in deeper layer IV adjacent to the white matter (Figures 20, 21 and 22). Prominent staining of neurons was also observed for the 150 mg dose group (Figure 23). In all animals (30–150 mg dose groups), no significant differences in neuronal idursulfase staining were observed between the frontal, middle, and occipital regions of the brain.

[0228] Idursulfase staining was positive in the spinal cord of all animals, with the highest staining intensity in the lumbar region (Figures 24 and 25). Idursulfase immunostaining was also dose-dependent. Neurons, meningeal cells, glial cells, perivascular cells and the epi- / peri- / endoneurium surrounding nerve fibers (connective cells) were strongly positive for idursulfase staining in the 150 mg group.

[0229] In the liver, positive staining for idursulfase was seen in sinusoidal cells (Kupffer cells and endothelial cells) of all animals. However, idursulfase was not detectable in hepatocytes for the 3 mg treatment group (Fig. 28), whereas positive idursulfase staining in hepatocytes was found in the higher dose groups, with the greatest staining intensity in the 150 mg treatment group (Figs. 29, 30 and 31).

[0230] In animals from the 3 mg treatment group, there was no positive staining for idursulfase. In contrast, interstitial cells stained positive for idursulfase in the 30, 100 and 150 mg groups, with significant staining in the 150 mg group, in terms of positive cell number and staining intensity (Figures 33, 34 and 35). kidney

[0231] Little or no injected idursulfase was detected in animals from the 3 mg dose group (Fig. 36). However, positive idursulfase staining was noted in glomerular and interstitial cells in the 30 and 100 mg groups. In the 150 mg group, idursulfase immunostaining further revealed idursulfase staining of proximal tubule cells, in addition to prominent staining of glomerular and hepatic cells (Fig. 39). Consideration

[0232] There were no test article related clinical signs or effects on body weight, food consumption, physical examination findings, or neurological examination findings. On Day 1, Group 4 (150 mg) animals showed a minimal tendency to move into the hind quarters within 3-12 minutes after dosing and lasting for 5-15 minutes; this sign was determined to be test article related.

[0233] Idursulfase administration was associated with a dose-dependent increase in idursulfase activity in various brain regions, as well as in the brainstem and spinal cord. The highest level of staining intensity in the spinal cord was in the lumbar region, where IT administration of idursulfase occurred. IT administration of idursulfase also resulted in systemic exposure with dose-dependent staining intensity in the liver, kidney, and heart. Animals receiving doses of test article at 30 mg and above showed a trend toward a more pronounced eosinophilic component of the inflammatory response in the meninges, but this difference is not considered biologically significant.

[0234] IT administration of idursulfase at doses up to 150 mg delivered at monthly intervals had no side effects. Therefore, the no observed adverse effect level (NOAEL) was taken to be 150 mg, the highest dose in this example. Idursulfase administration was associated with a dose-dependent increase in idursulfase in the CNS, resulting in systemic levels in the liver, kidney, and heart. Example 3: PK of IT delivered I2S (serum and CSF)

[0235] This example provides serum and cerebrospinal fluid (CSF) analyses associated with a 6-month toxicity study of idursulfase administered via monthly bolus intrathecal lumbar injection and weekly bolus intrathecal lumbar injection in cynomolgus monkeys for test article (TA) concentration. Experimental design

[0236] The objective of this study is to evaluate repeated dose intrathecal (IT) administration of idursulfase (I2S) from a toxicological and safety pharmacological perspective over a 6 month period. The study design is shown in Table 8. [Table 8] Test substance Identification: Idursulfase IV dosage- (2.0mg / mL) IT Dosage - Izursulfase (0 mg / mL), Izursulfase (3 mg / mL), Izursulfase (30 mg / mL), Izursulfase (100 mg / mL) Assay Method:

[0237] To determine the concentration of izursulfase, the assay was performed using ELISA (enzyme-linked immunosorbent assay). The detection limit value (IOD) before multiplying the dilution factor was 1.25 ng / mL. The samples were screened at a 1:50 dilution, and thus, the assay sensitivity was 62.5 ng / mL. Samples that dropped below the high endpoint of the calibration curve were further diluted and retested at an appropriate dilution that yielded values within the calibration curve range. The selected samples were further analyzed using an enzyme activity assay. The LOD for this assay was 0.18 mU / mL at a minimum sample dilution of 1:50.

[0238] Animals in Group 1 and Group 2 were administered saline or vehicle, respectively, and all animals had izursulfase levels in the range between 138 ng / mL and <62.5 ng / mL (or <LOD) throughout the IV and IT dosing periods. Sixty-two of the 200 CSF samples tested from Group 1 and Group 2 showed levels of I2S above the assay LOD. Seven of these values were high (>1,000 ng / mL). One of the three other CSF samples collected and tested before IT dosing had I2S of 1,00 ng / mL or higher.

[0239] The samples were then tested for izursulfase activity. In each case, the results of the activity indicated the presence of I2S, and when the appropriate concentration of I2S was calculated based on the activity level, the results were within 20% of those obtained by antigen ELISA (see Table 9). CSF samples additionally randomly selected at antigen ELISA results <LOD were also tested using an enzyme activity assay to rule out any non-specific activity.

Table 9

[0240] In this study, serum and CSF samples were analyzed for idursulfase concentrations. Serum samples were collected according to the following schedule: IV administration: Before and 2 hours after doses 1-10, before and 4 hours after doses 11-23, and at autopsy. IT administration: pre-dose and 2 hours after doses 1 and 2, pre-dose and 4 hours after doses 3-6, and at autopsy. CSF samples were collected according to the following schedule: IV dosing: predose and 2 hours after dose 1, and 4 hours after doses 3 and 6. IT administration: pre-dose and 2 hours after doses 1 and 2, pre-dose and 4 hours after doses 3-6, and at autopsy.

[0241] In general, serum idursulfase was cleared more rapidly than CSF idursulfase.

[0242] Serum idursulfase levels in Group 1 and 2 animals dosed with saline or vehicle, respectively, were less than or equal to 138 ng / mL at all time points tested, with some animals having levels below the assay limit of detection (LOD).

[0243] A minority of CSF samples from groups 1 and 2 were at or above the assay LOD, with seven notable exceptions that yielded high levels (>1,000 ng / mL). One CSF sample taken from an animal prior to IT dose 3 also tested at or above 1,000 ng / mL idursulfase.

[0244] Samples yielding these outlying results were retested and confirmed. These samples were further tested for idursulfase enzyme activity. These activity results also confirmed high idursulfase levels within 20% of those obtained from the idursulfase mass assay.

[0245] The specificity of the activity assay was demonstrated within this sample population by randomly testing CSF samples with idursulfase mass units below the LOD, confirming that the idursulfase levels in these samples were indeed at the LOD (data not shown). Example 4: Formulation

[0246] This Example outlines the formulation development studies conducted to establish the formulation and pharmaceutical formulation of idursulfase-IT drug substance for Phase I / II clinical trials.

[0247] Due to limitations in suitable excipients for CNS delivery, formulation development efforts for intrathecal delivery of idursulfase have focused on reducing phosphate and polysorbate 20 levels while also maintaining equivalent stability to the I2S formulation for systemic delivery.

[0248] Three key screening stress tests were performed to examine the effect of phosphate and polysorbate levels. These tests included freeze-thaw, shaking stress, and heat stress. The results showed that the saline formulation was more stable to freeze-thaw stress at low protein concentrations (2 mg / mL). At high protein concentrations (100 mg / mL), freeze-thaw stress did not cause instability issues for both saline- and phosphate-containing formulations. The shaking stress test confirmed that 0.005% polysorbate 20 protected the protein against shaking-related stress. The heat stability test demonstrated that the saline formulation was more stable compared to the phosphate-containing formulation. Furthermore, the pH of the saline formulation could be maintained at 6.0 for 24 months at 2-8°C. It was observed that the amount of residual phosphate bound to the protein, as well as increasing protein concentration, contributed to the pH stability in the final formulation. method Effect of freeze / thaw stress on the stability of idursulfase in saline and phosphate formulations

[0249] To study the effect of freeze / thaw on idursulfase stability in different formulations, SEC pools of vials were exchanged / concentrated four times into either 150 mM NaCl or 137 mM NaCl containing 20 mM sodium phosphate (both at pH 6.0) using Centriction Plus. Protein concentrations were targeted to reach 2 mg / ml and 100 mg / ml. All solutions were filtered through 0.22 micrometer PVDF filters. Solutions were divided into 1 mL aliquots each into 2 mL borosilicate glass vials. The vials were placed in the middle shelf of a lyophilization chamber and surrounded by placebo vials. Samples were frozen using a programmed freeze / thaw cycle (hold at 20°C for 1 hour, freeze to -50°C at 1°C / min). They were then thawed in two steps (thawing from −50° C. to −25° C. at 0.03° C. / min, holding at −25° C. for 24 h, and thawing to 2–8° C.) After two or three freeze / thaw cycles, samples were analyzed visually and by SEC-HPLC analysis. Effect of shaking / shear stress on idursulfase in phosphate and saline formulations.

[0250] Shaking tests were performed with idursulfase at different protein concentrations. Protein concentrations were tested at 2 mg / mL, 8 mg / mL, and 90-100 mg / mL in the presence of 137 mM NaCl in 20 mM phosphate, pH 6.0, and 154 mM NaCl alone, pH 6.0. Various amounts of PS-20 were spiked into the test conditions to see if polysorbate was necessary. The solutions were split into equal portions of 1.2 mL each into 2 mL glass vials and then shaken for 24 hours on a gyratory shaker at 250 rpm under ambient conditions. At baseline and 24 hours, the samples were inspected visually and 0.1 mL aliquots were taken and kept frozen at ≤-65°C in 0.5 mL polypropylene tubes until analysis by SEC-HPLC.

[0251] To first determine the impact of polysorbate 20 levels, a simulated shipping test was performed using a 3-hour truck shipment of the material, followed by a 1-hour airtight test at assurance level 1 using the random testing option (performed by Lansmont, Lansing, MI). Samples were analyzed by SEC-HPLC for particle appearance and soluble aggregates.

[0252] To study the effect of agitation stress on stability, saline formulations (50 mg / mL, 154 mM NaCl, and 0.005% PS-20) were filled at 1.3 mL into 3 mL glass vials containing Teflon magnetic stir bars (8 mm long and 2 mm diameter) and stopped with 13 mm stoppers. The vials were placed on a stir plate set at a speed of 6 (setting 6 was selected as the maximum speed without excessive foaming). Appearance was determined at 0, 2, 24, 48, and 72 hours. Baseline and 72 hour agitated samples were tested by SEC-HPLC method. Thermal stability testing for lead formulations

[0253] Six lead formulations were compared for thermal stability. The formulations were selected based on two parameters. The first parameter was the protein concentration required within the therapeutic window for CNS delivery. The second parameter was to control for the effect of phosphate concentration on stability. The vial filtered SEC pool was then centrifuged using a Centrifugation column. The mixture was buffer exchanged and concentrated using Plus-80. Target concentrations of 50 and 100 mg / mL protein were obtained. Six formulations were spiked with 1% polysorbate 20 solution for a final concentration of 0.01% PS-20. The material was filtered through a 0.22 micrometer PVDF filter and 0.5 mL was added to a 2 mL borosilicate glass vial. The vials were placed inverted for loading stability (40°C), accelerated stability (25°C), and real-time storage (2-8°C). Stability samples at each time point were tested by SEC-HPLC, OD320, SAX-HPLC, SDS-PAGE (Commassie), pH, and activity. Understanding stability in saline formulations

[0254] To understand how pH is maintained in saline formulations, the following study was performed. Phosphate Residue Testing in Saline Preparations

[0255] The vial-filtered SEC pool (2 mg / mL izursulfase, 137 mM NaCl, 20 mM sodium phosphate, pH 6.0) was diluted with 100% ethanol and purified using a Millipore TFF system and a Millipore Pellicon Biomax 30, 50 cm 2 The protein was concentrated using a filter and diafiltered into 150 mM NaCl. The amount of phosphate bound to the protein was determined after 7X, 10X and 15X cycles of diafiltration into 0.9% saline (prepared in TK3). In addition, the permeate after 10X diafiltration (protein-free flow through the filter) and the saline used in the filtration were also tested. Determination of the effect of protein concentration on pH

[0256] Protein impact studies were performed to better understand the control of pH in the absence of buffer (phosphate). To determine protein contribution to pH, materials were diluted in 154 mM NaCl (saline) to 30 mg / mL, 10 mg / mL, 2 mg / mL, 1 mg / mL, 0.1 mg / mL, and saline alone. Materials were aliquoted into 2 mL polypropylene tubes with a fill volume of 1 mL per tube. Samples were frozen at ≦-65°C for 1 hour and thawed at ambient temperature for 30 minutes, with this cycle repeated 3 times. The initial pH was measured and compared to that after 3X freeze / thaw cycles. The pH was also measured after 24 hours of ambient temperature exposure of the samples (by opening the caps of the tubes) to determine possible protein concentration effects on pH shifts.

[0257] Due to the limited availability of suitable excipients for CNS delivery, efforts to develop a formulation for intrathecal delivery of idursulfase focused on reducing phosphate and polysorbate 20 levels while maintaining equivalent stability to the I2S formulation for systemic administration. Three key screening stress tests were performed, including freeze-thaw, shaking stress, and heat stress. Effect of freezing / thawing on idursulfase in saline and phosphate preparations.

[0258] As shown in Table 10, at the low protein concentration of 2 mg / mL, the 20 mM phosphate-containing formulation produced more aggregates after freeze-thaw stress. The saline formulation remained at the same level of aggregates as at baseline. At the high protein concentration (100 mg / mL), freeze-thaw stress did not appear to affect the stability of either formulation (Table 11). This data suggested that the saline-only formulation had better stability to freeze-thaw stress. [Table 10] [Table 11] Effect of shaking stress on idursulfase in solution.

[0259] Shaking tests were performed at three protein concentration levels: 2, 8, and 100 mg / mL. The data showed that in the absence of polysorbate 20, precipitation occurred at all protein concentrations, and high levels of soluble aggregates were observed at 2 mg / mL (Tables 12-14). However, in the presence of low levels of P20, such as 0.005%, precipitation and soluble aggregates were largely suppressed. The data suggested that low levels of polysorbate were required to protect the protein against shaking stress. Tables 12-14: Shaking test in laboratory model (rotation at 250 rpm for 24 hours at ambient temperature) [Table 12] [Table 13] [Table 14]

[0260] To further confirm whether 0.005% is sufficient for shaking stability, simulated shipping studies, which approximate actual shipping conditions, were performed on saline formulations containing 100 mg / mL protein with different levels of polysorbate 20. The results confirmed that 0.005% was sufficient (Table 15). [Table 15]

[0261] The effect of agitation with a magnetic stir bar on saline formulations containing 50 mg / mL idursulfase with 0.005% polysorbate 20 is outlined in Table 16. As shown, the protein is not sensitive to the stress caused by agitation with a magnetic stir bar for 72 hours. The results also confirmed that 0.005% is sufficient for agitation stress. [Table 16] Thermal stability of lead candidates

[0262] Six key formulations were tested for stability over a 24-month period, and the results of these studies are discussed in this section. exterior

[0263] The appearance of all formulations remained slightly milky and essentially free of particles at all temperatures and time points tested for the six formulations. OD320

[0264] To examine potential increases in turbidity, OD320 values ​​were determined and are outlined in Table 17. As shown, with frozen storage, OD320 values ​​for all formulations remained similar to baseline after 24 months of storage. At 2-8°C conditions, the saline formulations remained similar to baseline, while the phosphate-containing formulations had increased levels in OD320 values. At the accelerated condition of 25°C, the saline formulations also had a slight increase in OD320 after 3-6 months, while the phosphate-containing formulations showed a more significant increase. These results suggest that the saline formulations are more stable to heat stress. [Table 17] SEC-HPLC

[0265] The data summary for all formulations tested by SEC-HPLC is shown in the table. Under frozen storage conditions, there were no changes after 24 months compared to baseline.

[0266] At 40°C stress conditions, all formulations had increased levels of soluble aggregates after 2 weeks. Furthermore, the phosphate-containing formulation also showed a "12 min" peak. However, after 1 month, this "12 min" peak observed in the phosphate-containing formulation appeared to disappear. Additionally, soluble aggregate levels did not increase further for all formulations compared to the 2 week time point (Figure 8 and Table 18).

[0267] At accelerated conditions of 25° C., increased levels of soluble aggregates were minimal after 6 months for all formulations compared to baseline, however, the phosphate-containing formulations showed a “12 minute” peak (FIG. 9 and Table 18).

[0268] At long-term storage conditions of 2-8°C, after 24 months, the increase in soluble aggregates for all formulations was also minimal after 24 months of storage. Consistent across all conditions, the phosphate-containing formulations also had a "12 minute peak" that increased slightly over time (Figure 10 and Table 18).

[0269] These results suggest that the saline formulations underwent minimal changes compared to the phosphate-containing formulations across all storage conditions. [Table 18] SAX-HPLC

[0270] The data summary for SAX-HPLC is displayed in Table 19. At stressed / accelerated conditions, the saline formulations appeared to have slightly more change (Figures 11 and 12), but at long-term storage conditions, there was no change after 24 months for all formulations (Table 19 and Figure 13). This indicates that the saline formulations are stable for 24 months at 2-8°C. [Table 19] pH

[0271] Table 20 shows that the pH of all formulations remained at a comparable pH to baseline for 24 months at 2-8° C. For the saline formulation, no buffer was present, but the pH remained constant at 6.0 for 24 months. [Table 20] Enzyme activity

[0272] Compared to the reference standard, after 24 months at 2-8°C the specific activities for all formulations were comparable within interassay variation, suggesting that idursulfase remains stable in saline formulations for 24 months (Table 21). [Table 21]

[0273] The final UF / DF step in the preparation of the saline formulation was used to diafilter the protein from 137 mM NaCl, 20 mM sodium phosphate to 150 mM NaCl. To examine how the number of diafiltration cycles affects the residual phosphate concentration in the final product, laboratory-scale studies were conducted with the drug substance (2 mg / mL idursulfase, 137 mM NaCl, 20 mM sodium phosphate, pH 6.0). The drug substance was first concentrated to 50 mg / mL idursulfase and then diafiltered into 150 mM saline. Samples were taken at the 7X, 10X, and 15X diafiltration steps and tested by ICP for phosphate content. The test results are summarized in Table 22. As shown, the saline diafiltrate solution does not contain any phosphate. After 7XDF, the protein contained about 0.22 mM phosphate, which was higher than theoretically calculated. After 10XDF, the flow-through was about 0.07 mM phosphate, while the protein retentate contained about 0.16 mM phosphate, suggesting that phosphate was bound to the protein. After 15XDF, the phosphate level dropped to about 0.07 mM.

[0274] Results from this study showed that approximately 0.2 mM phosphate residues remained in the drug substance, which likely contributed to the saline formulation maintaining a pH of 6.0. [Table 22] Effect of protein concentration on maintaining formulation pH

[0275] Phosphate content analysis revealed the binding of phosphate to protein. Therefore, it is expected that high concentration of protein can bind more phosphate, which may better maintain pH. To examine this hypothesis, protein in saline solution was concentrated to different levels and the pH of the solution after different treatment conditions was tested. The results are summarized in Table 23.

[0276] As shown, the initial pH of the solutions was maintained at about 6.0 depending on the protein concentration. However, after 24 hours of exposure to ambient temperature or after three freeze-thaw cycles, the pH of solutions containing 0.1 mg / mL or less of protein did not maintain a constant pH around 6.0. At protein concentrations of 1 mg / mL or more, the pH of the solutions was maintained around 6.0. This confirmed that protein concentration was a controlling factor in maintaining the pH of the saline solution. [Table 23]

[0277] Results from this study demonstrated that idursulfase in a saline formulation (50 mg / mL idursulfase, 0.005% polysorbate, 150 mM NaCl, pH 6.0) was stable for at least 24 months when stored at 2-8°C. This formulation appears to be more stable compared to phosphate-containing formulations. The selection of 0.005% polysorbate 20 was sufficient to protect the protein against shaking stress. Furthermore, this study also showed that the pH of the saline formulation could be stably maintained at 6.0 for 24 months at 2-8°C, which is partially due to the residual phosphate and high protein concentration in the final formulation. Example 5: Biodistribution

[0278] Having successfully demonstrated that intrathecal administration is an effective method of delivering I2S to tissues of the CNS, additional studies were performed to determine whether IT administered I2S is capable of distribution to deep brain tissues, as well as whether there is cellular localization of IT administered I2S. Recombinant human iduronate-2-sulfatase (I2S) preparations were prepared and formulated in a vehicle of 154 mM NaCl, 0.005% polysorbate 20 at a pH of 6.0.

[0279] Non-human primates received either 3 mg, 30 mg, or 100 mg of I2S monthly via an implanted intrathecal port for six consecutive months. The study design is outlined in Table 24 below. [Table 24]

[0280] Repeated monthly administration of I2S to non-human primates for 6 months was well tolerated at the highest dose tested and was not associated with any significant adverse toxicological events. Twenty-four hours after administration of the sixth and final dose of I2S, the subject non-human primates were sacrificed and CNS tissues of such non-human primates were examined.

[0281] There was widespread cellular deposition of I2S throughout cells and tissues of the CNS as determined by immunohistochemistry (IHC). I2S protein was detected in all tissues of the brain by IHC, with a deposition gradient from the cerebral cortex to the ventricular white matter. In the gray matter, I2S was detected in neurons of the cerebrum, cerebellum, brainstem, and spinal cord in a dose-dependent manner in all groups. In the superficial gray matter of the high-dose group, the majority of brain neurons were positive for I2S staining in the superficial cortex (Figure 40A). I2S was also detected in neurons within the thalamus (Figure 40B), hippocampus (Figure 40C), caudate nucleus (Figure 40D), and spinal cord (Figure 40E). Meningeal and perivascular cells were also positive for I2S staining (Figure 40F).

[0282] As shown in Figures 41 and 42, IT-administered I2S is distributed to tissues of the CNS of the subject non-human primate, particularly to the gray matter, thalamus, and cerebral cortex. Furthermore, Figures 42 and 43 illustrate that IT-administered I2S accumulates in the indicated CNS tissues of the subject non-human primate in a dose-dependent manner. Colocalization staining also revealed that IT administration of I2S binds to both neurons and oligodendrocytes. IT-administered I2S also distributes and localizes throughout the cerebrum of the subject non-human primate, as demonstrated by Figure 44. In particular, Figure 45 illustrates the neuronal uptake and axonal binding of I2S following IT administration to the subject non-human primate, as shown by filament staining. Of particular interest, the present studies also demonstrate that I2S is selective for neuronal cells, which facilitate the distribution of intrathecally administered I2S to deep brain tissues and appear to associate with axonal structures, suggesting anterograde axonal transport of I2S.

[0283] Table 25 below presents pharmacokinetic data for various routes of administration and dosages for individual animal studies. [Table 25]

[0284] As shown in Table 26 below, 124 I-labeled I2S was administered to test animals and the PET scan results are shown in Figures 62 and 63. [Table 26]

[0285] This study also demonstrated the cellular localization of IT-administered I2S in periventricular white matter brain tissue of subject non-human primates following IT administration. Although I2S staining density in white matter was generally lower than in gray matter, I2S was detected within oligodendrocytes (Figure 46). Notably, Figure 46 shows the cellular localization of I2S in white matter brain tissue, further demonstrating that I2S does not appear to bind to myelin.

[0286] In addition to demonstrating the deep distribution of IT administered I2S in brain tissue, this study also confirmed the localization of I2S to targeted organelles, importantly to lysosomes, the organelles affected in lysosomal storage diseases such as Hunter syndrome. Notably, I2S was localized within lysosomes and was also detected within axons. Figure 46 shows the localization of IT administered I2S within lysosomes of oligodendrocytes in subject non-human primates, thus confirming that IT administered I2S is capable of deep distribution in brain tissue as well as subcellular localization.

[0287] To determine whether the delivered I2S retained biological activity, levels of I2S in the brain were measured using a specific activity assay. Activity in the brain of the 3 mg IT group 24 hours after the last dose was not significantly different from basal levels in device and vehicle control animals. Enzyme activity in the brain of animals administered 30 mg and 100 mg IT was above baseline at the time of necropsy (24 hours after dosing).

[0288] Further animal studies to determine the biodistribution of I2S following IT delivery to the brain are shown in Figure 60, with sample numbers corresponding to Table 27 below. [Table 27] Example 6: IT versus ICV delivery

[0289] The I2S distribution observed in the previous examples was also reproduced in healthy beagle dogs administered a single IT or ICV dose. Male beagle dogs were randomly assigned into two groups (group 1 (ICV), N=3; group 2 (IT), N=4) using computer-generated numbers. All beagle dogs had catheters implanted in the lumbar subarachnoid space or left lateral ventricle (for administration) as well as in the cisterna magna (for sampling). All catheters were terminated in subcutaneous titanium access ports. An additional dog served as a non-administered surgical control.

[0290] A single bolus 1 mL injection of I2S (30 mg / mL in 20 mM sodium phosphate, pH 6.0; 137 mM sodium chloride; 0.02% polysorbate-20) was administered IT or ICV, followed by a 0.3 mL flush with phosphate-buffered saline (PBS; pH 7.2). Mice were monitored for clinical signs and sacrificed 24 h after administration. Brain and spinal cord tissue samples were collected for quantitative I2S analysis as determined by ELISA, I2S enzyme activity, and IHC and compared between study groups.

[0291] As determined by IHC, I2S was widely distributed throughout the gray matter in both IT and ICV groups. In the cerebral cortex, neurons were positive for I2S in six neurons from the superficial molecular layer to the deep inner layer in both IT and ICV groups, as shown by Figure 47 (A and B). In the cerebral cortex of the IT and ICV groups, I2S was detected in neurons including Purkinje cells, as shown by Figure 47 (C and D). In both IT and ICV groups, a large population of neurons in the hippocampus was positive for I2S, as shown by Figure 47 (E and F). I2S-positive neurons were also identified in the thalamus and caudate nucleus in both groups, as shown by Figure 47 (G and H).

[0292] Thus, this study confirms the ability of IT administered enzymes for deep cellular and tissue distribution in the brain, as well as supporting the utilization of enzymes such as IT administered I2S for the treatment of CNS manifestations associated with lysosomal storage diseases such as Hunter syndrome. Example 7: Iduronate-2-sulfatase-deficient animal model

[0293] Having established that IT-administered I2S is capable of deep tissue distribution in the brain as well as the subcellular localization of I2S, further studies were performed to determine the therapeutic efficacy of IT-administered I2S. To test the ability of IT-administered I2S to modify disease progression, a genetically engineered iduronate-2-sulfatase knockout (IKO) mouse model of Hunter syndrome was developed. This I2S knockout mouse model was developed with a targeted disruption of the I2S locus that results in the accumulation of glycosaminoglycans (GAGs) in tissues and organs. The IKO mouse model exhibits many of the physical characteristics of Hunter syndrome seen in humans, including characteristic facial and skeletal abnormalities. Additionally, the IKO mouse model shows elevated levels of glycosaminoglycans (GAGs) in urine and tissues throughout the body, as well as extensive cellular vacuolization observed histopathologically.

[0294] In this study, commercially available I2S (Elaprase®) was concentrated and resuspended in phosphate-buffered saline (PBS). Six groups of 8-12 week old male IKO mice were treated with I2S (10 μl; 26 mg / ml). Groups A and B (N=3) were administered three 260 μg doses (on days 1, 8, and 15) and two 260 μg doses (on days 1 and 8) of I2S intrathecally, respectively. Group D was also treated with three intrathecal doses of 260 μg on days 1, 8, and 15. Groups C and E (N=3) were untreated control groups, and group F (N=3) was an untreated wild-type control. Control mice were administered vehicle without I2S. Mice were sacrificed 1 hour after the last injection, followed by tissue preparation for immunohistochemistry (IHC) and histopathological analysis.

[0295] After the third injection, there was a widespread reduction in intracellular vacuolization in the superficial cerebral cortex, caudate nucleus, thalamus, and cerebellum in I2S-treated mice compared to vehicle-treated mice. Reductions in intracellular vacuolization were also identified in the white matter after IT treatment. Distribution of I2S to brain tissue of IKO mice was evident after IT administration.

[0296] Three weeks of IT administration of I2S in IKO mice also showed a significant reduction in CNS intracellular vacuolation at both light and electron microscopy levels. The reduction in intracellular vacuolation after IT administration of I2S was evident versus untreated IKO mice, suggesting that IT-administered I2S can modify disease progression. As shown in Figure 48, the reduction in cellular vacuolation was prominent in the corpus callosum and fornix of IKO mice after IT administration of I2S. Figure 49 shows a significant reduction in the presence of lysosomal-associated membrane protein 1 (LAMP1), a pathological biomarker of lysosomal disease, in the cerebral cortex tissue of treated IKO mice.

[0297] Furthermore, electron microscopy demonstrated a reduction in the presence of storage inclusions in neurons in the gray matter and vacuolation in oligodendrocytes in the white matter. In particular, I2S administered IT to IKO mice demonstrated a reduction in palisaded lamellar bodies (zebra bodies), a hallmark of certain lysosomal storage diseases. In particular, Figure 5 depicts electron microscopy scans showing a reduction in the characteristic zebra bodies in neurons of IKO mice administered I2S versus untreated IKO mice. Similarly, Figure 5 depicts electron microscopy scans of oligodendrocytes in the corpus callosum.

[0298] In addition, IT administration of I2S to IKO mice also demonstrated a significant reduction in lysosomal disease pathology biomarker lysosomal associated membrane protein 1 (LAMP1) immunostaining, an indicator of lysosomal activity and pathology, in the superficial cerebral cortex, caudate nucleus, thalamus, cerebellum and white matter. As shown in Figure 49A, a significant reduction in LAMP1 immunostaining was evident in the superficial cerebral cortex tissue of treated IKO mice versus the superficial cerebral cortex tissue of untreated IKO control mice shown in Figure 49B, reflecting an improvement in pathology.

[0299] Figure 20 shows the μm 2 The concentrations of LAMP-1 measured in the regions are illustrated and compared. Morphometric analysis of LAMP-1 immunostaining of various brain regions confirmed that there was a significant decrease in LAMP-1 positive staining in the brain regions evaluated. As shown in FIG. 4, in each region of brain tissue evaluated (cortex, caudate and putamen (CP), thalamus (TH), cerebellum (CBL) and white matter (WM)), the LAMP-1 positive area was decreased in treated IKO mice relative to untreated IKO control mice and approached the LAMP-1 positive area of ​​wild-type mice. Of particular note, the LAMP-positive area in each region of brain tissue analyzed was further decreased with continued treatment time.

[0300] The reduction in abnormally high lysosomal activity correlated with dramatic morphological improvements in all brain regions. These results confirm that IT-administered I2S can alter the progression of lysosomal storage disease in a genetically engineered IKO mouse model, as well as further support the ability of enzymes such as IT-administered I2S to treat CNS manifestations associated with lysosomal storage diseases such as Hunter syndrome. Example 8: Treatment of Hunter Syndrome Patients

[0301] Direct CNS administration, for example through IT delivery, can be used to effectively treat patients with Hunter syndrome. This example shows a multicenter dose escalation study designed to evaluate the safety of up to 40 weeks of three-phase every other week (EOW) I2S administration via an intrathecal drug delivery device (IDDD) in patients with late childhood Hunter syndrome. Various exemplary intrathecal drug delivery devices suitable for human treatment are shown in Figures 45-48.

[0302] Twenty patients were planned to be enrolled: Cohort 1: 5 patients (lowest dose) Cohort 2: 5 patients (intermediate dose) Cohort 3: 5 patients (highest dose) Five patients will be randomized to no treatment.

[0303] Patients were selected for study based on the following criteria for study inclusion: (1) onset of first symptoms before age 30 months; (2) ability to attend screening (defined as ability to stand independently and walk 10 steps forward with one hand support); and (3) presence of neurological signs at screening. Typically, patients with a history of hematopoietic stem cell transplantation are excluded.

[0304] The safety of a 40-week dose-escalating study of I2S administered by IT injection in children with late childhood Hunter syndrome will be determined. In addition, the clinical activity of I2S on global motor function, as well as single- and repeat-dose pharmacokinetics in serum and cerebrospinal fluid (CSF) concentrations will be evaluated.

[0305] A therapeutically effective amount of I2S is administered intrathecally at regular intervals, depending on the nature and extent of the disease's effects, and depending on the progression criteria. As used herein, administration at "intervals" refers to a therapeutically effective amount being administered periodically (as distinguished from a one-time administration). This interval can be determined by standard clinical techniques. In some embodiments, I2S is administered intrathecally approximately every other week. The administration interval for a single individual need not be a fixed interval, but can vary over time depending on the individual's needs. For example, if anti-I2S antibodies become present or increase during physical illness or stress, or if the disease condition worsens, the interval between administrations can be reduced. Example 9: Treatment of Hunter Syndrome Patients

[0306] Direct CNS administration, for example through IT delivery, can be used to effectively treat patients with Hunter syndrome. This example shows a multicenter dose escalation study designed to evaluate the safety of up to three phases of monthly I2S administration for a total of six months via an intrathecal drug delivery device (IDDD) in patients with late childhood Hunter syndrome. Various exemplary intrathecal drug delivery devices suitable for human treatment are shown in Figures 45-48, and a study schematic is shown in Figure 62.

[0307] Up to 16 patients will be enrolled. Population 1: 4 patients (minimum dose - 10mg) Cohort 2: 4 patients (mid-dose - 30mg) Cohort 3: 4 patients (highest dose - 100mg) Four patients will be randomized to no treatment or no device use.

[0308] Hunter syndrome patients frequently manifest cognitive and neurodevelopmental disorders including delays in early developmental stages (e.g., walking, language, toilet training), intellectual deficiencies, hyperactivity, aggression, hearing impairment, epilepsy, and hydrocephalus. All of these indicators may be part of the criteria for study inclusion. Patients are selected for study based on the following criteria for study inclusion: (1) age between 3 and 18 years; (2) intelligence quotient below 77 or a decline of 15 to 30 IQ points in the past 3 years; (3) absence of CSF blockage or poorly controlled seizure disorder, and (4) absence of comorbidities that present anesthesia and / or surgical risk.

[0309] The safety of escalating doses of I2S administered by IT injection over a 6-month period in children with late childhood Hunter syndrome will be determined. In addition, the clinical activity of I2S on gross motor function, as well as single- and repeat-dose pharmacokinetics in serum and cerebrospinal fluid (CSF) concentrations will be evaluated.

[0310] The objectives of this study will be to evaluate the safety and tolerability of escalating doses of I2S, as well as the safety, tolerability and long-term patency of IDDD. In addition, the concentrations of I2S in CSF and peripheral blood after single and repeated IT administration, as well as the effects of I2S on CF biomarkers and urinary GAGs will be evaluated. Further evaluations will include the effects of I2S on clinical parameters such as physiological and neurocognitive assessments, neurological function and brain structure volumes. In addition, the effects of treatment on daily life and the relationships between biomarkers and symptoms may be evaluated.

[0311] Treatment of Hunter syndrome patients with IT delivery of I2S reduces the accumulation of sulfatides in various tissues (e.g., nervous system, heart, liver, kidneys, gallbladder, and other organs).

[0312] While the compounds, compositions and methods described herein are specifically described in accordance with certain embodiments, the following examples are merely illustrative of the compounds of the invention and are not intended to be limiting thereof.

[0313] The articles "a" and "an" as used in the specification and claims should be understood to include plural referents unless expressly stated otherwise. A claim or description including "or" between one or more elements of a group is intended to be satisfied if one, more than one or all of the group elements are present in, used in or relevant to a given product or process, unless expressly stated otherwise or clear from the context. The invention includes embodiments in which exactly one element of a group is present in, used in or relevant to a given product or process. The invention also includes embodiments in which more than one element or all elements of a group are present in, used in or relevant to a given product or process. Furthermore, the invention should be understood to encompass all modifications, combinations and permutations of one or more limitations, elements, clauses, descriptive language, etc. of one or more recited claims incorporated into another claim dependent on the base claim (or as any other claim associated therewith) unless expressly stated otherwise or unless it would be apparent to one of ordinary skill in the art that a contradiction or inconsistency would result. Where elements are listed (e.g., in a Markush group or similar format), it should be understood that each subgroup of elements is also disclosed and that any element(s) may be excluded from the group. In general, when the invention or aspects of the invention are said to include certain elements, features, etc., it should be understood that a particular embodiment of the invention or a particular aspect of the invention consists of, or consists essentially of, such elements, features, etc. For the sake of brevity, these embodiments are not specifically described in this specification in every instance. It should also be understood that any embodiment or aspect of the invention may be expressly excluded from the claims, regardless of whether it is specifically described herein as excluded. Publications, websites and other reference materials referenced in this specification to describe the background of the invention and to provide further details regarding the practice of the invention are incorporated herein by reference.

Claims

1. 1. A pharmaceutical composition for treating Hunter Syndrome, comprising an iduronate-2-sulfatase (I2S) enzyme, the composition being administered intrathecally (IT) or intracerebroventricularly (ICV) to a patient suffering from or susceptible to Hunter Syndrome, the composition comprising an I2S at a concentration of at least 5 mg / ml and up to 20 mM phosphate, the composition having a pH of 5.5 to 7.

0.

2. 10. The pharmaceutical composition of claim 1, further characterized in that I2S is present at a concentration of 10 mg / ml.

3. The pharmaceutical composition of claim 1 or 2, wherein the composition further comprises a surfactant.

4. 4. The pharmaceutical composition of claim 3, further characterized in that the surfactant is present in a concentration of 0.005% to 0.2%.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the composition further comprises an isotonicity agent.

6. The composition of any one of claims 1 to 5, wherein the composition is administered in a single dose volume of less than 5 mL or less than 3 mL.

7. The composition of any one of claims 1 to 6, wherein administration of said composition does not result in substantial adverse events and / or does not result in an adaptive T cell mediated immune response in said patient.

8. The composition of any one of claims 1 to 7, wherein administration of the composition comprises intrathecal administration.

Citation Information

Patent Citations

  • Delivery of therapeutic compounds to the brain and other tissues

    JP2007504166A

  • JPP6938456B